{"data":[{"id":"a473062d-a414-4e79-a0a1-f3695fc1b1d2","public_id":"MfgaSwoj","name":"이재련","canonical_name":"이재련","type":"individual","role":null,"bio":"이재련 is a South Korean medical oncologist at Seoul Asan Medical Center and University of Ulsan College of Medicine specializing in genitourinary cancers, including prostate, kidney, bladder, and metastatic urologic tumors. He became director of Seoul Asan's Genitourinary Cancer Center in March 2024 and has led or participated in multicenter oncology trials through Korean professional societies. Public reporting also shows him presenting high-profile oncology data at ASCO, indicating influence through research, clinical leadership, and specialist networks rather than investment activity.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/a473062d-a414-4e79-a0a1-f3695fc1b1d2.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["oncology","genitourinary cancer","prostate cancer","kidney cancer","bladder cancer","metastatic urologic tumors","immuno-oncology","precision oncology","theranostics","clinical trials"],"connections":[],"source_urls":["https://www.amc.seoul.kr/asan/staff/base/staffBaseInfoDetail.do?drEmpId=QmtVa1dENUhYYTNUbWpOQm1SNUcyZz09","https://news.amc.seoul.kr/news/con/detail.do?cntId=8360","https://www.ksmo.or.kr/Pages/About/about04_04.aspx","https://www.kcsg.org/m/clinical/clinicalView.do?clinIdx=11","https://www.amc.seoul.kr/asan/depts/D312/K/bbsDetail.do?contentId=273950&menuId=4038","https://m.healthcaren.com/news/news_article_yong.jsp?mn_idx=525175","https://news.amc.seoul.kr/news/con/detail.do?cntId=10214"],"is_person":true,"person_tags":["key_employee"],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is for a real human being with a personal Korean name, the prior `type` is `individual`, and the bio describes his roles as a medical oncologist and research leader rather than any organization.","classified_at":"2026-06-04T01:07:14.909Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Seoul Asan Medical Center identifies 이재련 as professor of oncology and, since March 2024, director of its Genitourinary Cancer Center. Hospital and society sources also show him leading clinical research and serving as chair of the Korean Society of Medical Oncology's insurance-policy committee, which supports an ecosystem-influencer classification rather than a capital-deployer role.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investments, fund ownership, or disclosed equity stakes were found in reputable sources. The available evidence identifies him as a physician-scientist and clinical oncology leader.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Seoul Asan Medical Center identifies 이재련 as professor of oncology and, since March 2024, director of its Genitourinary Cancer Center. Hospital and society sources also show him leading clinical research and serving as chair of the Korean Society of Medical Oncology's insurance-policy committee, which supports an ecosystem-influencer classification rather than a capital-deployer role.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-06-03T23:55:28.948Z","updated_at":"2026-06-21T21:55:30.924Z","entities":[{"entity_name":"Seoul Asan Medical Center","entity_type":"company","role":"professor of oncology; director of Genitourinary Cancer Center","url":"https://www.amc.seoul.kr/asan/staff/base/staffBaseInfoDetail.do?drEmpId=QmtVa1dENUhYYTNUbWpOQm1SNUcyZz09"},{"entity_name":"University of Ulsan College of Medicine","entity_type":"advisory","role":"faculty professor","url":"https://www.amc.seoul.kr/asan/staff/base/staffBaseInfoDetail.do?drEmpId=QmtVa1dENUhYYTNUbWpOQm1SNUcyZz09"},{"entity_name":"Korean Society of Medical Oncology","entity_type":"advisory","role":"chair, insurance-policy committee","url":"https://www.ksmo.or.kr/Pages/About/about04_04.aspx"},{"entity_name":"Korean Cancer Study Group","entity_type":"advisory","role":"clinical trial principal investigator; board member listed in annual report","url":"https://www.kcsg.org/m/clinical/clinicalView.do?clinIdx=11"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/MfgaSwoj","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"e390cb55-3a21-47a9-96e5-fdeb55622ca4","public_id":"XuO4BiDp","name":"장명호","canonical_name":"장명호","type":"individual","role":null,"bio":"장명호 is a South Korean biotech founder and immunology-trained executive best known as the founder and CEO of GI Innovation, a listed immuno-oncology and protein therapeutics company founded in 2017. His official biography includes prior roles as Principal Investigator at IBS, Professor at Osaka University IFReC, Scientific Advisor at Genexine, and CSO at Progen. He is also publicly listed by GI Cell as its founder and Chief Clinical Scientific Advisor.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/e390cb55-3a21-47a9-96e5-fdeb55622ca4.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["biotech","immuno-oncology","protein therapeutics","cell therapy","translational research","drug development"],"connections":[{"name":"홍준호","relationship":"co-CEO at GI Innovation"},{"name":"이병건","relationship":"board/executive colleague at GI Innovation; company advisor and former chairman/CEO"}],"source_urls":["https://www.gi-innovation.com/en/sub/company/member.asp","https://www.gi-innovation.com/kr/sub/pr/media.asp?bid=3&idx=40&mode=view&page=1&s_cate=&s_keyword=&s_type=","https://www.ibtomato.com/View.aspx?no=13974&type=1","https://stockanalysis.com/quote/kosdaq/358570/market-cap/","https://www.exchange-rates.org/exchange-rate-history/krw-usd","https://www.gi-cell.com/en/sub/about/member.asp","https://event.hankyung.com/kiw2025/"],"is_person":true,"person_tags":["uhnwi","key_employee"],"entity_category":null,"classification_confidence":{"uhnwi":0.78},"classification_reasoning":"The row names a real human being with an individual type and a personal biography describing Jang Myung-ho as the founder/CEO of GI Innovation and other named executive and academic roles, not a legal entity.","classified_at":"2026-06-04T01:17:52.140Z","role_kind":"capital_owner","role_kind_evidence":"[owner] GI Innovation's official site identifies Jang as the founder, and the company previously stated he was its largest shareholder. A January 7, 2025 IBTomato report, citing disclosure data, says he held 6.76% (3,054,806 shares) of GI Innovation, which is documented equity ownership in a named company. | [ecosystem] GI Innovation's official executive page lists Jang as founder and CEO, with prior roles including Principal Investigator at IBS and Professor at Osaka University IFReC. GI Cell's official executive page also lists him as Founder / Chief Clinical Scientific Advisor, indicating scientific and company-building influence rather than fund management.","is_capital_owner":true,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"GI Innovation's official site identifies Jang as the founder, and the company previously stated he was its largest shareholder. A January 7, 2025 IBTomato report, citing disclosure data, says he held 6.76% (3,054,806 shares) of GI Innovation, which is documented equity ownership in a named company.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"GI Innovation's official executive page lists Jang as founder and CEO, with prior roles including Principal Investigator at IBS and Professor at Osaka University IFReC. GI Cell's official executive page also lists him as Founder / Chief Clinical Scientific Advisor, indicating scientific and company-building influence rather than fund management.","personal_capital_usd":"47200000","personal_capital_text":"~$47.2M","personal_capital_source_url":"https://www.ibtomato.com/View.aspx?no=13974&type=1","personal_capital_reasoning":"Estimated from Jang's disclosed 6.76% GI Innovation stake (3,054,806 shares) reported by IBTomato from disclosure data, multiplied by GI Innovation's April 27, 2026 market cap of KRW 1.03T from StockAnalysis. Using the April 27, 2026 KRW/USD rate of 0.0006784 gives an implied stake value of roughly KRW 69.6B, or about $47.2M. This is a market-value estimate of one documented holding, not a full net-worth calculation.","personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":"~$47.2M","net_worth_source_url":"https://www.ibtomato.com/View.aspx?no=13974&type=1","net_worth_reasoning":"Estimated from Jang's disclosed 6.76% GI Innovation stake (3,054,806 shares) reported by IBTomato from disclosure data, multiplied by GI Innovation's April 27, 2026 market cap of KRW 1.03T from StockAnalysis. Using the April 27, 2026 KRW/USD rate of 0.0006784 gives an implied stake value of roughly KRW 69.6B, or about $47.2M. This is a market-value estimate of one documented holding, not a full net-worth calculation.","future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":"2026-09-11T05:45:21.114Z","dossier_last_refreshed_at":"2026-09-11T05:50:08.885Z","created_at":"2026-06-03T23:55:28.958Z","updated_at":"2026-09-27T04:20:03.071Z","entities":[{"entity_name":"GI Innovation","entity_type":"company","role":"ceo","url":"https://www.gi-innovation.com/en/sub/company/member.asp"},{"entity_name":"GI Cell","entity_type":"advisory","role":"chief clinical scientific advisor","url":"https://www.gi-cell.com/en/sub/about/member.asp"},{"entity_name":"Genexine","entity_type":"advisory","role":"scientific advisor","url":"https://www.gi-innovation.com/en/sub/company/member.asp"},{"entity_name":"Progen","entity_type":"company","role":"cso","url":"https://www.gi-innovation.com/en/sub/company/member.asp"},{"entity_name":"Institute for Basic Science (IBS)","entity_type":"advisory","role":"principal investigator","url":"https://www.gi-innovation.com/en/sub/company/member.asp"},{"entity_name":"Osaka University IFReC","entity_type":"advisory","role":"professor","url":"https://www.gi-innovation.com/en/sub/company/member.asp"}],"labels":[],"funding_events_count":0,"public_content_count":240,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/XuO4BiDp","relevance":"relevant","personal_capital_estimate":{"is_estimate":true,"value_usd":47200000,"value_text":"~$47.2M","source_url":"https://www.ibtomato.com/View.aspx?no=13974&type=1","reasoning":"Estimated from Jang's disclosed 6.76% GI Innovation stake (3,054,806 shares) reported by IBTomato from disclosure data, multiplied by GI Innovation's April 27, 2026 market cap of KRW 1.03T from StockAnalysis. Using the April 27, 2026 KRW/USD rate of 0.0006784 gives an implied stake value of roughly KRW 69.6B, or about $47.2M. This is a market-value estimate of one documented holding, not a full net-worth calculation.","observed_at":null},"fund_aum_estimate":null,"net_worth_estimate_note":{"is_estimate":true,"value_text":"~$47.2M","source_url":"https://www.ibtomato.com/View.aspx?no=13974&type=1","reasoning":"Estimated from Jang's disclosed 6.76% GI Innovation stake (3,054,806 shares) reported by IBTomato from disclosure data, multiplied by GI Innovation's April 27, 2026 market cap of KRW 1.03T from StockAnalysis. Using the April 27, 2026 KRW/USD rate of 0.0006784 gives an implied stake value of roughly KRW 69.6B, or about $47.2M. This is a market-value estimate of one documented holding, not a full net-worth calculation."}},{"id":"4b5ed017-7047-4130-bf5f-0cc31cb90a09","public_id":"9exIdMmO","name":"1004 Venture Partners","canonical_name":"1004 venture partners","type":"vc","role":null,"bio":"Venture capital firm focused on healthy aging and longevity biotech investments.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name includes the firm-style term 'Venture Partners' and the bio explicitly describes it as a venture capital firm, indicating a legal investment entity rather than a human being.","classified_at":"2026-05-05T07:05:23.298Z","role_kind":null,"role_kind_evidence":"not_relevant: 1004 Venture Partners is an organization, not an individual. Its official site describes it as \"a global specialist fund\" and LinkedIn lists it as a venture capital firm, so the record fits the \"organization stored in a person field\" rule rather than a person with documented personal capital deployment.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-20T20:00:58.397Z","updated_at":"2026-05-28T01:30:02.492Z","entities":[],"labels":[{"slug":"longevity","confidence":1},{"slug":"biotech","confidence":1}],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/9exIdMmO","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"33e41bd1-da4b-40c4-a4bf-a181474b0b0c","public_id":"rs4fbaId","name":"100+ Capital","canonical_name":null,"type":null,"role":null,"bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://100pluscap.com"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name contains 'Capital' and the website describes 100 Plus Capital as an investing organization that 'invests in companies,' which is decisive evidence of an entity rather than a human being.","classified_at":"2026-06-04T02:54:34.388Z","role_kind":null,"role_kind_evidence":"not_relevant: 100+ Capital appears to be an organization, not an individual. Vector describes 100Capital Inc. as the group's investment business in Tokyo, and PitchBook/Crunchbase profile it as a VC/growth-investment firm rather than a person deploying personal wealth.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-06-03T01:13:55.987Z","updated_at":"2026-06-04T02:54:34.388Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/rs4fbaId","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"13e8c25b-7f92-499e-b7df-5a4dad247fdc","public_id":"gVcWHr7T","name":"100 Plus Capital","canonical_name":null,"type":"vc","role":"private_investor","bio":"... 100 Plus Capital, and is a venture partner at Portfolia, where she ... Dr. Ayesha Khanna's Post. View profile for Dr. Ayesha Khanna · Dr ...","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"https://image.pitchbook.com/lJQWr2UjfxIXZPgypu3WwQYSfEd1580987755869_200x200","crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://www.linkedin.com/posts/ayeshakhanna_ai-activity-7416690474293575680-T5eU"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name contains the corporate investment term \"Capital,\" and the row’s type/role describe an investing organization rather than an individual human.","classified_at":"2026-05-08T06:35:50.996Z","role_kind":null,"role_kind_evidence":"not_relevant: This record is an organization, not an individual. 100 Plus Capital's site describes it as an investment firm that invests in companies impacting human longevity, and multiple sources identify Sonia Arrison as its founder; no personal-capital concept applies to this entity record.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-27T22:32:22.968Z","updated_at":"2026-05-12T03:06:27.666Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/gVcWHr7T","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"0180c525-e621-490d-b388-8367e73c77b2","public_id":"HQLmo87L","name":"10FT Ventures","canonical_name":"10ft ventures","type":"vc","role":null,"bio":"Venture capital and venture building firm specializing in digital health, precision medicine, and longevity, with a focus on corporate venture building and healthcare innovation.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name '10FT Ventures' includes 'Ventures' and the bio describes a venture capital firm, which indicates a for-profit investment entity rather than a human being.","classified_at":"2026-05-01T21:25:42.754Z","role_kind":null,"role_kind_evidence":"not_relevant: 10FT Ventures is an organization, not an individual. I found no reputable-source evidence of personal wealth, angel activity, family-office principal status, or personal equity holdings attributable to a person named 10FT Ventures.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-20T15:03:11.533Z","updated_at":"2026-05-23T06:00:03.745Z","entities":[],"labels":[{"slug":"longevity","confidence":1},{"slug":"biotech","confidence":1},{"slug":"medicine","confidence":1}],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/HQLmo87L","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"055e1c54-480a-4c66-a86d-1f447a268b90","public_id":"yifkgSFP","name":"116 Street Ventures","canonical_name":null,"type":"vc","role":"private_investor","bio":"Bob E. 116 Street Ventures Investor. Columbia University. See testimonial policy below. Meet Our Managing Partner. Ludwig Pierre Schulze, EMBA '05. Ludwig has ...","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/055e1c54-480a-4c66-a86d-1f447a268b90.png","crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://av.vc/funds/116street/ohs-calendly"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name contains 'Ventures' and the cited source describes 116 Street Ventures as an Alumni Ventures venture capital fund/community rather than an individual human.","classified_at":"2026-05-18T22:23:15.640Z","role_kind":null,"role_kind_evidence":"not_relevant: 116 Street Ventures is an organization, not an individual. Official Alumni Ventures and LinkedIn pages describe it as a venture capital fund/community, so personal capital ownership does not apply.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-29T01:44:59.429Z","updated_at":"2026-05-18T22:23:15.640Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/yifkgSFP","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"9e2d7678-559f-44cc-aca0-b4e86e9ed6c4","public_id":"q6KW5mI5","name":"1843 Capital","canonical_name":"1843 capital","type":"vc","role":null,"bio":"1843 Capital is an early-stage venture capital firm founded in 2016 by Tracy Killoren Chadwell, a lawyer-turned-investor with 15+ years in venture capital and private equity. The firm focuses primarily on AgeTech and Longevity — technology for older adults and the 100+ year healthspan — alongside FinTech and Cybersecurity, with a strong emphasis on diverse and female-founded teams. Notable exits include Beautycounter ($1B valuation) and Tempo Automation (Nasdaq: TMPO).","url":null,"linkedin_url":"https://www.linkedin.com/company/1843-capital","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":["agetech","longevity","healthtech","digital health","biotech","fintech","cybersecurity","consumer","CPG","women-led companies","diverse founders","AI","workforce technology"],"connections":[{"name":"Tracy Killoren Chadwell","relationship":"Founding Partner — the primary decision-maker and public face of 1843 Capital"},{"name":"Ken Hall","relationship":"Former advisor to 1843 Capital; venture capital and emerging tech specialist"},{"name":"Aeppel (Developer)","relationship":"Chairman of 1843 Capital Advisory Board"},{"name":"Peter Kaldes","relationship":"Discussed AgeTech investments publicly alongside Tracy Chadwell"},{"name":"Avestria Ventures","relationship":"Co-investor network — listed alongside 1843 Capital in shared portfolio context"},{"name":"Able Partners","relationship":"Co-investor — appears in same syndicate context as 1843 Capital"},{"name":"Black Angel Group","relationship":"Co-investor — appears in same syndicate context as 1843 Capital"}],"source_urls":["https://1843capital.com/about-1843-capital/","https://1843capital.com/","https://1843capital.com/resources/","https://www.sbc.senate.gov/public/_cache/files/5/a/5ad547b9-cf40-4af7-84c2-c81665e51632/1DC52D8253A0DF41C78ADC26AAB833EE.chadwell-testimony.pdf","https://thegerontechnologist.com/tracy-chadwell-podcast/","https://beyondthebillion.com/our-partners/1843-capital/","https://www.crunchbase.com/organization/1843-capital","https://pitchbook.com/profiles/investor/182200-96","https://tracxn.com/d/venture-capital/1843capital/__X5msCPkSy3RFXQVFOD6NgiFfZgBHgf3BNuqIvPWjhzg","https://superscout.co/investor/1843-capital","https://arivc.com/ken-hall-sn2-14b/","https://www.hotelinvestmenttoday.com/Development/Owners/Developer-Ae","https://connect.visible.vc/investors/1843-capital","https://app.dealroom.co/investors/1843_capital"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name includes the investment-firm term \"Capital,\" the type is \"vc,\" and the bio explicitly describes 1843 Capital as an early-stage venture capital firm founded by Tracy Killoren Chadwell.","classified_at":"2026-05-10T20:04:39.174Z","role_kind":null,"role_kind_evidence":"not_relevant: 1843 Capital is an organization, not an individual. Its official site and Crunchbase describe it as an early-stage venture capital firm, so personal-capital ownership criteria for a natural person do not apply.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":"No publicly disclosed AUM or fund size found in available sources. Portfolio of ~19 companies across pre-seed through Series A suggests a fund in the $20M–$60M range typical for boutique AgeTech-focused early-stage VCs, but this is unverified.","future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-20T13:45:55.172Z","updated_at":"2026-05-12T07:42:53.074Z","entities":[{"entity_name":"1843 Capital","entity_type":"fund","role":"founder","url":"https://1843capital.com"},{"entity_name":"Beyond The Billion","entity_type":"advisory","role":"partner/member","url":"https://beyondthebillion.com/our-partners/1843-capital/"},{"entity_name":"Beautycounter","entity_type":"company","role":"early investor (exited)","url":null},{"entity_name":"Tempo Automation","entity_type":"company","role":"early investor (Nasdaq: TMPO)","url":null},{"entity_name":"Function Health","entity_type":"company","role":"investor","url":null},{"entity_name":"Midi Health","entity_type":"company","role":"investor","url":"https://1843capital.com/joins-1843-capital-as-partner/"},{"entity_name":"Manta Cares","entity_type":"company","role":"investor","url":null},{"entity_name":"Rippl Care","entity_type":"company","role":"investor","url":null}],"labels":[{"slug":"longevity","confidence":1},{"slug":"startup","confidence":1}],"funding_events_count":2,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/q6KW5mI5","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"b130df46-db5f-4477-8fbc-e7acc5fae3ff","public_id":"mp2ueFaH","name":"2048 Ventures","canonical_name":"2048 ventures","type":"vc","role":null,"bio":"Pre-seed and seed-stage VC firm focused on Vertical AI, Deep Tech, Healthcare, and Biotech, investing from an $82M Fund III.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name includes 'Ventures' and the bio explicitly describes it as a pre-seed and seed-stage VC firm managing Fund III, which indicates a commercial investment entity rather than a human.","classified_at":"2026-05-03T21:51:04.113Z","role_kind":null,"role_kind_evidence":"not_relevant: 2048 Ventures is an organization, not an individual. Under the schema's not_relevant rule for organizations stored in a person field, personal capital ownership does not apply.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-20T17:24:35.893Z","updated_at":"2026-05-16T18:10:02.281Z","entities":[],"labels":[{"slug":"ai-ml","confidence":1},{"slug":"biotech","confidence":1}],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/mp2ueFaH","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"47f7c4d7-e7ba-4d16-9512-8dad58346b88","public_id":"Hr4ezKVY","name":"2Go Advisory Group","canonical_name":"https://image.pitchbook.com/BhIi7D5EI0sLjEJI7UJw4hoyfYd1649756499177_200x200","type":"vc","role":"private_investor","bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"Glen C Terry is over 65 years old. Glen's current address is 6400 S Mason ... They work as a Partner, Cfos to Go at 2GO Advisory Group. Cell Phone. Glen ...","crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://www.whitepages.com/name/Glen-Terry"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name contains the organizational term \"Advisory Group,\" and public web results describe 2Go Advisory Group as a business consulting/services firm rather than an individual person.","classified_at":"2026-06-03T21:14:32.645Z","role_kind":null,"role_kind_evidence":"not_relevant: No documented personal capital deployment was found. Primary sources describe 2GO Advisory Group as a business consulting, fractional C-suite, advisory, and recruiting firm rather than a person, family office principal, or investing entity.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-06-02T09:05:45.533Z","updated_at":"2026-06-03T21:14:32.645Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/Hr4ezKVY","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"b0ed8a2a-3630-4490-9885-d6637d083661","public_id":"GsoiFQTl","name":"515 Ventures","canonical_name":"https://image.pitchbook.com/rWDTJfVwmyikoVEAbXPK2EdgzE81762253613446_200x200","type":"vc","role":"private_investor","bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"515 Ventures was founded in 2017 by Frederic Kerrest, Vice Chairman & Co-Founder at Okta, Managing Partner & Founder at Windproof Partners, and author of ...","crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://www.515ventures.com/about"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The source page describes 515 Ventures as an investment firm founded by Frederic Kerrest and explicitly shows the legal name '515 Ventures LLC,' which indicates an entity rather than a human.","classified_at":"2026-07-03T09:11:15.438Z","role_kind":null,"role_kind_evidence":"not_relevant: 515 Ventures is an organization, not an individual. The official site describes it as a venture firm founded by Frederic Kerrest, and the SEC Form D identifies 515 Ventures, LLC as the issuer.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-06-30T23:23:26.291Z","updated_at":"2026-07-03T09:11:15.438Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/GsoiFQTl","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"fb6d655c-0fa3-4097-a6ba-3282b178ddc2","public_id":"tcJDD2bX","name":"5AM Opportunities II (GP), LLC","canonical_name":null,"type":"vc","role":"private_investor","bio":"5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are ...","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://investors.camp4tx.com/static-files/ee14033b-e0c5-40a9-9bb1-2d54d99ee794"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The row names a legal entity with explicit corporate suffixes \"(GP), LLC,\" and the bio states it is the sole general partner of a fund, which identifies it as a fund management entity rather than a human.","classified_at":"2026-05-18T22:14:10.604Z","role_kind":null,"role_kind_evidence":"not_relevant: This is not a natural person but a Delaware LLC that appears in SEC filings as the sole general partner of 5AM Opportunities II, L.P. There is no documented personal net worth or personal angel activity because the record is an organization.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-29T01:41:56.735Z","updated_at":"2026-05-18T22:14:10.604Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/tcJDD2bX","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"999e13aa-dea6-4876-940c-05358cd385a7","public_id":"Ukcs9Bef","name":"5AM Partners V","canonical_name":null,"type":"vc","role":"private_investor","bio":"5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V ... /s/ Kush Parmar. 11/18/2025. ** Signature of Reporting Person. Date. Reminder ...","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://ir.entradatx.com/static-files/2adca760-ac73-4ba6-9e8b-ab4aa34b6c49"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name includes the fund-style term \"Partners\" and the bio explicitly identifies \"5AM Partners V, LLC\" as a legal entity serving as a sole general partner.","classified_at":"2026-05-18T22:17:53.381Z","role_kind":null,"role_kind_evidence":"not_relevant: This is not a natural person. SEC filings identify 5AM Partners V, LLC as the sole general partner of 5AM Ventures V, L.P., so the record is an organization mistakenly stored as a person rather than an individual with documented personal capital deployment.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-29T01:42:01.774Z","updated_at":"2026-05-18T22:17:53.381Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/Ukcs9Bef","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"16d58117-bcd9-48b2-8abc-200208f84ad2","public_id":"Mhza2eDe","name":"5AM Partners VII, LLC","canonical_name":null,"type":"vc","role":"private_investor","bio":"5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing ...","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://investors.camp4tx.com/static-files/ee14033b-e0c5-40a9-9bb1-2d54d99ee794"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name includes the corporate suffix \"LLC\" and the bio describes it as the sole general partner of a venture fund, which identifies it as a legal investment entity rather than a human.","classified_at":"2026-05-18T22:06:21.589Z","role_kind":null,"role_kind_evidence":"not_relevant: This is an organization, not a person. SEC filings describe 5AM Partners VII, LLC as the sole general partner of 5AM Ventures VII, so there is no documented personal net worth, angel activity, or other personal capital deployment attributable to an individual.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-29T01:41:54.093Z","updated_at":"2026-05-18T22:06:21.589Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/Mhza2eDe","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"c80df44a-1ccc-480f-810e-d68bf88496f2","public_id":"j7xV3vM1","name":"5AM Ventures","canonical_name":"5am ventures","type":"vc","role":"private_investor","bio":"Kush Parmar, M.D., Ph.D. Managing Partner at 5AM Ventures. 5AM Ventures Harvard Medical School. Boston, Massachusetts, United States.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/c80df44a-1ccc-480f-810e-d68bf88496f2.png","crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://www.linkedin.com/in/kush-parmar-m-d-ph-d-5165582"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The row name is '5AM Ventures' and the cited public sources describe it as a venture capital firm, so this is an investment entity rather than a human being.","classified_at":"2026-05-18T21:58:47.823Z","role_kind":null,"role_kind_evidence":"not_relevant: This record is an organization, not an individual. I found no documented personal net worth, angel activity, or personal equity holdings attributable to a person named \"5AM Ventures.\"","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-29T01:41:50.784Z","updated_at":"2026-08-26T11:20:10.495Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/j7xV3vM1","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"07f5f16a-a532-4baf-9659-95c50708cdae","public_id":"YQ0dEdlP","name":"600and1","canonical_name":"600and1","type":"vc","role":null,"bio":"Longevity-focused biotech startup operating a fund alongside internal research initiatives aimed at decoding and bioengineering aging. Invests at the intersection of combinatorial aging research and biotechnology.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The row describes a longevity-focused biotech startup that operates a fund and makes investments, which is a for-profit organization rather than a human being.","classified_at":"2026-05-13T14:56:10.778Z","role_kind":null,"role_kind_evidence":"not_relevant: 600and1 appears to be an organization rather than an individual. Its official website describes it as a \"biotechnology longevity unicorn startup,\" and multiple press releases describe it as a biotechnology startup, venture incubator, and venture fund; no reputable source documents personal capital deployment by a person named 600and1.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-20T15:11:22.559Z","updated_at":"2026-05-13T14:56:10.778Z","entities":[],"labels":[{"slug":"longevity","confidence":1},{"slug":"biotech","confidence":1},{"slug":"basic-research","confidence":1},{"slug":"science","confidence":1}],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/YQ0dEdlP","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"eecc9229-e9c3-4c68-bfc8-5445ff68ebeb","public_id":"awgSSX9F","name":"7wire Ventures","canonical_name":"7wire ventures","type":"vc","role":null,"bio":"Healthcare-focused VC firm investing across the longevity market, with thesis segments spanning Agetech & Cognitive Health, Therapeutics & Drug Discovery, Cellular Rejuvenation, and Consumer Diagnostics & Care.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name includes 'Ventures' and the bio explicitly describes it as a healthcare-focused VC firm, indicating a for-profit investment entity rather than a human being.","classified_at":"2026-05-04T04:52:08.916Z","role_kind":null,"role_kind_evidence":"not_relevant: 7wire Ventures is an organization, not an individual. No documented personal capital deployment or personal net worth applies to this record.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-20T17:44:10.990Z","updated_at":"2026-05-12T09:26:24.424Z","entities":[],"labels":[{"slug":"longevity","confidence":1},{"slug":"biotech","confidence":1},{"slug":"drug-discovery","confidence":1},{"slug":"medicine","confidence":1}],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/awgSSX9F","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"68e62164-1f05-4717-b705-82933ed3f54c","public_id":"WwUmBkKp","name":"8VC","canonical_name":"8vc","type":"vc","role":null,"bio":"8VC is a San Francisco-based early-stage venture capital and bio-sciences investment firm founded by Joe Lonsdale, Jake Medwell, and Drew Oetting, managing over $6 billion in capital across six funds. The firm operates both as a traditional VC and an internal venture studio (the 'Build' program), co-founding approximately 25-30% of its portfolio companies. Portfolio highlights include Palantir, Anduril Industries, Guardant Health, Ramp, and Orca Bio.","url":null,"linkedin_url":"https://www.linkedin.com/company/8vc","twitter_handle":"@8VC","x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":["enterprise software","defense tech","bio-sciences","longevity","cell therapy","healthcare IT","AI","fintech","logistics","transportation","govtech","deep tech","robotics","autonomous systems","data infrastructure"],"connections":[{"name":"Joe Lonsdale","relationship":"Founder and Managing Partner of 8VC; PayPal mafia alumnus; co-founded Palantir with Peter Thiel"},{"name":"Jake Medwell","relationship":"Co-founder of 8VC; leads logistics/transportation practice; serial entrepreneur"},{"name":"Drew Oetting","relationship":"Co-Founding Partner of 8VC; co-founder of Affinity; board at AgVend"},{"name":"Peter Thiel","relationship":"Network peer; Founders Fund co-invests with 8VC (e.g. Anduril); Lonsdale co-founded Palantir with Thiel"},{"name":"Andreessen Horowitz (a16z)","relationship":"Frequent co-investor (e.g. Anduril joint rounds)"},{"name":"Founders Fund","relationship":"Co-investor in Anduril and other defense/deep tech deals"},{"name":"Vivek Ramaswamy","relationship":"LP in 8VC Fund III ($500K–$1M stake per public disclosures)"}],"source_urls":["https://8vc.com/","https://8vc.com/team/joe-lonsdale","https://www.8vc.com/team/jake-medwell","https://alejandrocremades.com/drew-oetting/","https://www.8vc.com/resources/announcing-8vc-fund-vi","https://www.8vc.com/companies/orca-bio","https://www.vcsheet.com/fund/8vc","https://startupintros.com/orgs/8vc","https://vc-mapping.gilion.com/vc-firms/8vc","https://app.dealroom.co/investors/8vc","https://www.sourcery.vc/p/how-8vc-builds-billion-dollar-companies","https://ohiocapitaljournal.com/2026/04/21/vivek-ramaswamy-may-have-stake-in-company-receiving-more-than-830-million-from-ohio/"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The row is for 8VC, a venture capital firm managing multiple funds and identified by corporate branding, firm bio, company LinkedIn, and fund AUM rather than a real human individual.","classified_at":"2026-05-10T20:05:10.449Z","role_kind":null,"role_kind_evidence":"not_relevant: 8VC is an organization, not an individual. No personal net worth, personal angel activity, or other individual wealth signal applies to this record.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":"$6B+ AUM","net_worth_source_url":"https://8vc.com/team/joe-lonsdale","net_worth_reasoning":"8VC's own website states Joe Lonsdale manages 'over $6 billion in capital' at 8VC. Fund VI alone closed at $998M in new LP capital per their announcement post, corroborating the $6B+ cumulative AUM figure.","future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-20T13:55:13.333Z","updated_at":"2026-05-12T07:44:53.050Z","entities":[{"entity_name":"8VC Fund VI","entity_type":"fund","role":"manager","url":"https://www.8vc.com/resources/announcing-8vc-fund-vi"},{"entity_name":"8VC Build (Venture Studio)","entity_type":"company","role":"operator","url":"https://www.vcsheet.com/fund/8vc"},{"entity_name":"Palantir Technologies","entity_type":"company","role":"early investor / co-founder (Lonsdale)","url":"https://www.palantir.com"},{"entity_name":"Anduril Industries","entity_type":"company","role":"investor","url":"https://www.anduril.com"},{"entity_name":"Guardant Health","entity_type":"company","role":"investor","url":"https://guardanthealth.com"},{"entity_name":"Orca Bio","entity_type":"company","role":"investor","url":"https://www.8vc.com/companies/orca-bio"},{"entity_name":"Ramp","entity_type":"company","role":"investor","url":"https://ramp.com"},{"entity_name":"Cognition (Devin AI)","entity_type":"company","role":"investor","url":"https://cognition.ai"},{"entity_name":"OpenGov","entity_type":"company","role":"investor","url":"https://opengov.com"},{"entity_name":"Addepar","entity_type":"company","role":"investor / co-founded (Lonsdale)","url":"https://addepar.com"},{"entity_name":"Affinity","entity_type":"company","role":"board (Oetting co-founder)","url":"https://affinity.co"},{"entity_name":"AgVend","entity_type":"company","role":"board (Oetting)","url":"https://agvend.com"},{"entity_name":"Lineage Logistics","entity_type":"company","role":"technology advisor (Medwell)","url":"https://lineagelogistics.com"},{"entity_name":"Chapter","entity_type":"company","role":"investor (Series E, April 2026)","url":"https://startupintros.com/orgs/8vc"}],"labels":[{"slug":"biotech","confidence":1},{"slug":"longevity","confidence":1}],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/WwUmBkKp","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":{"is_estimate":true,"value_text":"$6B+ AUM","source_url":"https://8vc.com/team/joe-lonsdale","reasoning":"8VC's own website states Joe Lonsdale manages 'over $6 billion in capital' at 8VC. Fund VI alone closed at $998M in new LP capital per their announcement post, corroborating the $6B+ cumulative AUM figure."}},{"id":"6d5321bf-4c1b-44c0-9ee8-eb8bd7660b52","public_id":"2y4wMVWK","name":"Aakriti Garg Shukla","canonical_name":"aakriti shukla","type":"individual","role":"private_investor","bio":"Aakriti Garg Shukla, MD, MSc is a glaucoma and cataract specialist at Columbia University Irving Medical Center and NewYork-Presbyterian, where ColumbiaDoctors lists her as an Associate Professor of Ophthalmology. Her professional profile emphasizes clinical care, glaucoma research, surgical outcomes, and sustainability in ophthalmology. She also holds advisory and editorial roles with The Glaucoma Foundation, EyeSustain, and ophthalmology publications and committees.","url":null,"linkedin_url":"https://www.linkedin.com/in/aakriti-garg-shukla-md-msc-753a4420","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/6d5321bf-4c1b-44c0-9ee8-eb8bd7660b52.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["ophthalmology","glaucoma","cataract surgery","early glaucoma detection","glaucoma progression","surgical outcomes","healthcare disparities","telehealth screening","community-based research","cost-effectiveness","sustainability in ophthalmology","global eye health"],"connections":[{"name":"Lisa A. Hark","relationship":"Co-leads Columbia's CDC Vision Health Initiative coordinating center with Shukla"},{"name":"Jonathan S. Myers","relationship":"Frequent co-author and former Wills Eye colleague"},{"name":"Reza Razeghinejad","relationship":"Co-author and former Wills Eye glaucoma colleague"},{"name":"George A. Cioffi","relationship":"Co-author on glaucoma screening work at Columbia"}],"source_urls":["https://doctors.columbia.edu/us/ny/new-york/aakriti-garg-shukla-md-msc-622-w-168th-street","https://www.vagelos.columbia.edu/departments-centers/ophthalmology/about-us/contact-us","https://glaucomafoundation.org/our_staff/aakriti-garg-shukla-md/","https://glaucomafoundation.org/about-tgf/medical-advisory-board/","https://www.eyesustain.org/about/leadership","https://www.prnewswire.com/news-releases/thea-pharma-inc-launches-preservative-freedom-coalition-to-advocate-for-preservative-free-eye-care-301835329.html","https://glaucomafoundation.org/doctor-i-have-a-question-how-should-i-use-my-eye-drops/"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row identifies Aakriti Garg Shukla as an individual physician and professor, and the cited source pages describe her as a real human doctor holding clinical, academic, and advisory roles rather than a legal entity.","classified_at":"2026-05-18T00:50:32.976Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] ColumbiaDoctors identifies her as an Associate Professor of Ophthalmology at Columbia University Irving Medical Center and an attending ophthalmologist at NewYork-Presbyterian. The Glaucoma Foundation lists her on its Medical Advisory Board, and EyeSustain lists her as Chair of its Editorial Board, indicating a research/advisory influence role rather than a capital-deployment role.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, board-seat equity stake, family office principal role, or foundation endowment role was found in the reviewed reputable sources.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"ColumbiaDoctors identifies her as an Associate Professor of Ophthalmology at Columbia University Irving Medical Center and an attending ophthalmologist at NewYork-Presbyterian. The Glaucoma Foundation lists her on its Medical Advisory Board, and EyeSustain lists her as Chair of its Editorial Board, indicating a research/advisory influence role rather than a capital-deployment role.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-13T08:07:19.087Z","updated_at":"2026-05-18T01:20:03.391Z","entities":[{"entity_name":"Ophthalmology","entity_type":"advisory","role":"Editorial board member","url":"https://www.vagelos.columbia.edu/profile/aakriti-g-shukla-md"},{"entity_name":"NewYork-Presbyterian","entity_type":"company","role":"attending ophthalmologist","url":"https://doctors.columbia.edu/us/ny/new-york/aakriti-garg-shukla-md-msc-622-w-168th-street"},{"entity_name":"World Glaucoma Association","entity_type":"advisory","role":"associate advisory board member","url":"https://glaucomafoundation.org/our_staff/aakriti-garg-shukla-md/"},{"entity_name":"CDC Vision Health Initiative Coordinating Center at Columbia University","entity_type":"advisory","role":"Principal Investigator and co-lead; Chair, Clinical and Comparative-Effectiveness Working Group","url":"https://www.vagelos.columbia.edu/departments-centers/ophthalmology/research/research-areas/community-based-research/cdc-vision-health-initiative-coordinating-center-columbia-university"},{"entity_name":"Wills Eye Hospital","entity_type":"company","role":"former assistant professor of ophthalmology","url":"https://glaucomafoundation.org/our_staff/aakriti-garg-shukla-md/"},{"entity_name":"American Academy of Ophthalmology","entity_type":"advisory","role":"sustainability task force member","url":"https://glaucomafoundation.org/our_staff/aakriti-garg-shukla-md/"},{"entity_name":"American Glaucoma Society","entity_type":"advisory","role":"glaucoma screening task force member","url":"https://glaucomafoundation.org/our_staff/aakriti-garg-shukla-md/"},{"entity_name":"Columbia University Irving Medical Center","entity_type":"company","role":"associate professor of ophthalmology","url":"https://doctors.columbia.edu/us/ny/new-york/aakriti-garg-shukla-md-msc-622-w-168th-street"},{"entity_name":"The Glaucoma Foundation","entity_type":"foundation","role":"medical advisory board member","url":"https://glaucomafoundation.org/about-tgf/medical-advisory-board/"},{"entity_name":"American Society of Cataract and Refractive Surgery","entity_type":"advisory","role":"young eye surgeons clinical committee member","url":"https://glaucomafoundation.org/our_staff/aakriti-garg-shukla-md/"},{"entity_name":"EyeSustain","entity_type":"advisory","role":"editorial board chair","url":"https://www.eyesustain.org/about/leadership"},{"entity_name":"Ophthalmology Glaucoma","entity_type":"advisory","role":"editorial board member","url":"https://glaucomafoundation.org/our_staff/aakriti-garg-shukla-md/"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/2y4wMVWK","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"9bc02507-7faa-470f-949f-58ceb013db52","public_id":"C13r2Pwc","name":"Aakriti G Shukla","canonical_name":null,"type":"individual","role":null,"bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row has a real personal name with no corporate markers, and the prior `type` field is `individual`, with no evidence suggesting a legal entity.","classified_at":"2026-05-13T09:13:28.388Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Columbia University identifies Aakriti Garg Shukla, MD, MSc as an Associate Professor of Ophthalmology and attending ophthalmologist, which fits the professor/medical expert category. The Glaucoma Foundation profile also says she serves on multiple editorial and advisory boards, reinforcing an ecosystem-influence role rather than a capital-deployment role.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":"Columbia University identifies Aakriti Garg Shukla, MD, MSc as an Associate Professor of Ophthalmology and attending ophthalmologist, which fits the professor/medical expert category. The Glaucoma Foundation profile also says she serves on multiple editorial and advisory boards, reinforcing an ecosystem-influence role rather than a capital-deployment role.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T04:55:01.239Z","updated_at":"2026-05-13T09:13:28.388Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/C13r2Pwc","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"a8f6499d-a055-44a8-89c0-cfe1f0feebc4","public_id":"aWEtnYqi","name":"Aalim Weljie","canonical_name":"aalim weljie","type":"individual","role":null,"bio":"Aalim Weljie is a metabolomics researcher and Associate Professor at the Perelman School of Medicine at the University of Pennsylvania. He leads the Weljie Lab, where his work focuses on circadian and sleep metabolomics, cancer-related metabolic profiling, environmental toxicology, and analytical platforms including NMR and LC-MS. Earlier in his career he was affiliated with the University of Calgary before joining Penn in 2012.","url":null,"linkedin_url":"https://www.linkedin.com/in/aalim-weljie-9611822","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/a8f6499d-a055-44a8-89c0-cfe1f0feebc4.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["metabolomics","sleep biology","circadian rhythms","cancer biomarkers","translational medicine","environmental toxicology","NMR spectroscopy","LC-MS","lipidomics","aging"],"connections":[{"name":"Arjun Sengupta","relationship":"senior research investigator in Weljie Lab and frequent co-author/collaborator"},{"name":"Amita Sehgal","relationship":"co-author and research collaborator on sleep/circadian metabolomics work"},{"name":"John Hogenesch","relationship":"co-author on circadian metabolism research"},{"name":"Lisa Bottalico","relationship":"research collaborator in environmental/circadian toxicology work within Weljie Lab"}],"source_urls":["https://www.med.upenn.edu/weljielab/members.html","https://www.med.upenn.edu/apps/faculty/index.php/g20000321/p8555925","https://pmc.ncbi.nlm.nih.gov/articles/PMC5479132/","https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00106","https://www.linkedin.com/in/aalim-weljie-9611822"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names a specific individual and the bio/URLs describe Aalim Weljie as an Associate Professor and researcher at the University of Pennsylvania rather than a company or fund.","classified_at":"2026-05-11T11:41:57.299Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] University of Pennsylvania identifies Aalim M. Weljie, Ph.D. as an Associate Professor of Systems Pharmacology and Translational Therapeutics, and the Weljie Lab page identifies him as Principal Investigator. His research centers on circadian/sleep metabolomics, cancer metabolic profiling, and translational metabolomics, which makes him a scientific/domain influencer rather than a capital deployer.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No reputable source found showing personal capital deployment, angel investing, fund ownership, family-office principal status, or disclosed equity-based wealth. Available sources describe Weljie as an academic scientist and principal investigator.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"University of Pennsylvania identifies Aalim M. Weljie, Ph.D. as an Associate Professor of Systems Pharmacology and Translational Therapeutics, and the Weljie Lab page identifies him as Principal Investigator. His research centers on circadian/sleep metabolomics, cancer metabolic profiling, and translational metabolomics, which makes him a scientific/domain influencer rather than a capital deployer.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T04:20:01.590Z","updated_at":"2026-05-15T15:20:02.812Z","entities":[{"entity_name":"University of Pennsylvania","entity_type":"advisory","role":"associate professor","url":"https://www.med.upenn.edu/apps/faculty/index.php/g20000321/p8555925"},{"entity_name":"Perelman School of Medicine","entity_type":"advisory","role":"principal investigator","url":"https://www.med.upenn.edu/weljielab/members.html"},{"entity_name":"Weljie Lab","entity_type":"advisory","role":"principal investigator","url":"https://www.med.upenn.edu/weljielab/members.html"},{"entity_name":"University of Calgary","entity_type":"advisory","role":"former faculty/researcher","url":"https://www.med.upenn.edu/weljielab/members.html"},{"entity_name":"Institute for Translational Medicine and Therapeutics, University of Pennsylvania","entity_type":"advisory","role":"faculty affiliate","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5479132/"},{"entity_name":"Chronobiology and Sleep Institute, University of Pennsylvania","entity_type":"advisory","role":"research collaborator/affiliate","url":"https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00106"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/aWEtnYqi","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"e04ffc5b-051d-4681-b97b-fec970c1aa02","public_id":"gzaxjDuV","name":"Aanjay Ageless Ventures LLP","canonical_name":"aanjay llp","type":"other","role":"private_investor","bio":"Aanjay Ageless Ventures LLP is a small Indian angel/seed investment vehicle active in early-stage Indian startups, particularly in the religion-tech and consumer goods space. It has co-invested alongside Venture Catalysts and other Indian micro-VCs in companies such as OM Bhakti, Art of Puja, Satvik, ARTH, Seetara, and Gappl. The entity appears to be a family or individual investment LLP rather than a formal institutional fund, with no significant public-facing presence.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":["religion tech","consumer goods","Indian early-stage startups","e-commerce","spiritual products"],"connections":[{"name":"Mohit Anoop Mehta","relationship":"co-investor via shared portfolio on Tracxn; both listed as investors in the same Indian seed-stage companies"},{"name":"Ankit Mittal","relationship":"co-investor; both listed in Swastika Investmart-associated investment activity on Inc42"},{"name":"Venture Catalysts","relationship":"frequent co-investor in Indian religion-tech / consumer startups"}],"source_urls":["https://tracxn.com/d/companies/ombhakti/__QZv-cA8Z0tBvd-1PFIfYNEQTdS5MkrqLIcz1cYCADeE","https://tracxn.com/d/companies/artofpuja/__FDdNu6POOxzzQOGOMPVrCiSAM0LKDGZHpTR-kAMRP_A","https://tracxn.com/d/companies/satvik/__byJG0foeNsBA_kptBUQglDMS-nkuc8yIjG2ppBkzNnI","https://tracxn.com/d/companies/gappl/__242b_Cu83Dycvyy7UADOZZ1MNyCy-1VydmgVy9vKb0I","https://tracxn.com/d/companies/seetara/__3E8t2M5UhCwKXudSCi5aR9PJ4f5N-w95-w5QL5q6vJM","https://tracxn.com/d/people/mohit-anoop-mehta/__SqOzWK_X4B8bLr2ZAy5fGw0Uroma9J2cQtHYGdvpGRU","https://inc42.com/company/swastika-investmart/investments/","https://inc42.com/person/ankit-mittal/investments/","https://action-polyplast-private-limited.charteredone.com/U25191DL2012PTC237671","https://sos.ks.gov/publications/register/2020/Vol_39_No_48_November_26_2020_October_2020_Forfeitures.pdf"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name includes the corporate/legal suffix \"LLP\" and \"Ventures,\" and the bio describes it as an investment vehicle rather than a human individual.","classified_at":"2026-05-01T23:36:50.543Z","role_kind":null,"role_kind_evidence":"not_relevant","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-25T21:12:24.556Z","updated_at":"2026-05-13T04:00:03.338Z","entities":[{"entity_name":"Aanjay Ageless Ventures LLP","entity_type":"fund","role":"investor","url":null},{"entity_name":"OM Bhakti","entity_type":"company","role":"investor","url":"https://tracxn.com/d/companies/ombhakti/__QZv-cA8Z0tBvd-1PFIfYNEQTdS5MkrqLIcz1cYCADeE"},{"entity_name":"Art of Puja","entity_type":"company","role":"investor","url":"https://tracxn.com/d/companies/artofpuja/__FDdNu6POOxzzQOGOMPVrCiSAM0LKDGZHpTR-kAMRP_A"},{"entity_name":"Satvik","entity_type":"company","role":"investor","url":"https://tracxn.com/d/companies/satvik/__byJG0foeNsBA_kptBUQglDMS-nkuc8yIjG2ppBkzNnI"},{"entity_name":"Gappl","entity_type":"company","role":"investor","url":"https://tracxn.com/d/companies/gappl/__242b_Cu83Dycvyy7UADOZZ1MNyCy-1VydmgVy9vKb0I"},{"entity_name":"Seetara","entity_type":"company","role":"investor","url":"https://tracxn.com/d/companies/seetara/__3E8t2M5UhCwKXudSCi5aR9PJ4f5N-w95-w5QL5q6vJM"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/gzaxjDuV","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"011a3c5f-b890-4347-a8a8-fbfc740b69bd","public_id":"frlmDdVU","name":"A Ari Hakimi","canonical_name":null,"type":"individual","role":null,"bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is most consistent with a real human because the name is formatted as a personal name and the `type` field says `individual`, with no corporate or organizational indicators present.","classified_at":"2026-05-10T17:21:56.279Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Memorial Sloan Kettering identifies A. Ari Hakimi as a physician-scientist studying kidney cancers, which fits the ecosystem-influencer category for scientific experts. His publication record and research leadership indicate knowledge-network influence rather than capital deployment.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"Reputable sources identify A. Ari Hakimi as a urologic surgeon and physician-scientist at Memorial Sloan Kettering, and the available coverage located is medical/research-oriented rather than financial. I found no reputable evidence of personal wealth, angel investing, family-office/foundation principalship, or equity holdings/stakes.","evidence_fund_operator":"Memorial Sloan Kettering describes him as a urologic surgeon and physician-scientist, not as a GP, managing partner, CIO, venture partner, or other paid investment manager. No reputable source located ties him to operating a fund or institutional investment vehicle.","evidence_ecosystem_influencer":"Memorial Sloan Kettering identifies A. Ari Hakimi as a physician-scientist studying kidney cancers, which fits the ecosystem-influencer category for scientific experts. His publication record and research leadership indicate knowledge-network influence rather than capital deployment.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T04:20:01.612Z","updated_at":"2026-05-11T06:50:03.746Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/frlmDdVU","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"5711688d-3781-408f-8e18-c650715ed9e2","public_id":"KWJCcuer","name":"A. Ari Hakimi, MD","canonical_name":"a hakimi","type":"individual","role":"private_investor","bio":"A. Ari Hakimi, MD is a urologic surgeon and physician-scientist at Memorial Sloan Kettering Cancer Center in New York. His clinical and research work focuses on kidney tumors, renal cell carcinoma, cancer genomics, and the tumor microenvironment, and he leads the Hakimi Lab within MSK's Human Oncology & Pathogenesis Program. Public disclosures reviewed show academic and clinical leadership activity, not investment or fund-management activity.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/5711688d-3781-408f-8e18-c650715ed9e2.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["kidney cancer","renal cell carcinoma","urologic oncology","cancer genomics","tumor microenvironment","immunogenomics","cancer metabolism","translational medicine","robotic and minimally invasive surgery","biomarkers"],"connections":[{"name":"Robert J. Motzer","relationship":"MSK colleague and recurring co-author in kidney cancer research"},{"name":"Paul Russo","relationship":"MSK colleague and recurring co-author in urologic oncology research"},{"name":"Martin H. Voss","relationship":"MSK colleague and recurring co-author in renal cell carcinoma research"}],"source_urls":["https://www.mskcc.org/cancer-care/doctors/ari-hakimi","https://www.mskcc.org/research-areas/labs/ari-hakimi","https://www.mskcc.org/research-programs/human-oncology-pathogenesis/faculty","https://pmc.ncbi.nlm.nih.gov/articles/PMC9720541/","https://www.mskcc.org/sites/default/files/styles/width_600/public/node/35080/3x2/hakimi-a-ari-250228-06_rtc_1200x800.jpg"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names a specific human physician-scientist ('A. Ari Hakimi, MD') and all supporting evidence describes his individual clinical and academic roles rather than any separate legal entity.","classified_at":"2026-05-11T05:31:57.300Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Memorial Sloan Kettering identifies A. Ari Hakimi, MD as an Associate Attending Surgeon, urologic surgeon, and physician-scientist focused on kidney cancer, and its Human Oncology & Pathogenesis Program lists him as faculty and lab head. These roles make him a research and clinical opinion leader rather than a primary capital deployer.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, equity stakes, family-office/foundation principal role, or net-worth reporting was found in credible sources reviewed. Public sources describe Hakimi as a physician-scientist and surgeon at Memorial Sloan Kettering rather than an investor.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Memorial Sloan Kettering identifies A. Ari Hakimi, MD as an Associate Attending Surgeon, urologic surgeon, and physician-scientist focused on kidney cancer, and its Human Oncology & Pathogenesis Program lists him as faculty and lab head. These roles make him a research and clinical opinion leader rather than a primary capital deployer.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-10T17:16:52.857Z","updated_at":"2026-05-12T14:22:39.253Z","entities":[{"entity_name":"Sidney Kimmel Center for Prostate and Urologic Cancers","entity_type":"company","role":"urologic surgeon","url":"https://www.mskcc.org/cancer-care/doctors/ari-hakimi"},{"entity_name":"Human Oncology & Pathogenesis Program","entity_type":"advisory","role":"research leader","url":"https://www.mskcc.org/research-areas/labs/ari-hakimi"},{"entity_name":"The A. Ari Hakimi Lab","entity_type":"advisory","role":"Lab Head","url":"https://www.mskcc.org/research-areas/labs/ari-hakimi"},{"entity_name":"Memorial Sloan Kettering Cancer Center","entity_type":"company","role":"Associate Attending Surgeon; Urologic Surgeon","url":"https://www.mskcc.org/cancer-care/doctors/ari-hakimi"},{"entity_name":"Human Oncology & Pathogenesis Program, Memorial Sloan Kettering","entity_type":"advisory","role":"Faculty","url":"https://www.mskcc.org/research-programs/human-oncology-pathogenesis/faculty"},{"entity_name":"Merck & Co. Inc.","entity_type":"company","role":"Professional services and activities (uncompensated disclosure)","url":"https://www.mskcc.org/cancer-care/doctors/ari-hakimi"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/KWJCcuer","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"8f7fbbd0-a669-4092-9528-ab42fa4453e2","public_id":"bCobWpWO","name":"Aarin Capital","canonical_name":null,"type":"vc","role":"private_investor","bio":"Aarin Capital is a proprietary venture fund that invests in large technology-driven opportunities · Dr. Ranjan Pai · TV Mohandas Pai · Venkatesh K.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"https://image.pitchbook.com/vfA4F3nInlWrt8NXgAu4ZlPoU181764078874702_200x200","crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://aarincapital.com/about/"],"is_person":false,"person_tags":[],"entity_category":"commercial","classification_confidence":{},"classification_reasoning":"The name includes the corporate term \"Capital\" and the bio explicitly describes Aarin Capital as a proprietary venture fund, so this is an investment entity rather than a human being.","classified_at":"2026-05-18T13:40:31.481Z","role_kind":null,"role_kind_evidence":"not_relevant: Aarin Capital is an organization, not an individual. Its official site describes it as a proprietary venture fund, so under the schema it should be treated as an organization mistakenly stored in a person field.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-27T21:25:01.188Z","updated_at":"2026-05-18T13:40:31.481Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/bCobWpWO","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"ffaa56e3-49bc-4e22-908b-073c8654f45d","public_id":"ztEgACtH","name":"Aaron Boudreau","canonical_name":"aaron boudreau","type":"other","role":null,"bio":"Aaron Boudreau is a cancer and target-biology scientist based in the San Francisco Bay Area. LinkedIn lists him as Senior Director, Target Biology at Scorpion Therapeutics. His publication record includes research affiliated with Lawrence Berkeley National Laboratory, UCSF, and Genentech, with a focus on tumor biology, breast cancer progression, and oncology drug resistance.","url":null,"linkedin_url":"https://www.linkedin.com/in/aaron-boudreau-38046a78","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/ffaa56e3-49bc-4e22-908b-073c8654f45d.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["biotech","oncology","cancer biology","precision oncology","target biology","tumor microenvironment","drug resistance"],"connections":[{"name":"Mina J. Bissell","relationship":"co-authored cancer biology publications with her"},{"name":"Laura J. van 't Veer","relationship":"co-authored a UCSF-affiliated review article with her"},{"name":"Jeff Settleman","relationship":"co-authored Genentech oncology research with him"},{"name":"James Kiefer","relationship":"appears with Boudreau on Genentech/oncology publication records"}],"source_urls":["https://www.linkedin.com/in/aaron-boudreau-38046a78","https://pubmed.ncbi.nlm.nih.gov/24067649/","https://pubmed.ncbi.nlm.nih.gov/19160017/","https://pubmed.ncbi.nlm.nih.gov/25379179/","https://pubmed.ncbi.nlm.nih.gov/25681442/","https://www.tandfonline.com/doi/full/10.4161/cam.20880"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names a specific individual and the bio/LinkedIn/publication affiliations describe Aaron Boudreau as a human scientist rather than a legal organization.","classified_at":"2026-05-11T11:53:08.127Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] LinkedIn identifies Aaron Boudreau as Senior Director, Target Biology at Scorpion Therapeutics in San Francisco. PubMed records show him as an author on multiple oncology and cancer-biology publications affiliated with Lawrence Berkeley National Laboratory, UCSF, and Genentech, which supports classification as a scientific ecosystem contributor rather than a capital deployer.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investments, family-office/foundation principal role, or disclosed equity/board-stake wealth was found in the reviewed sources.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"LinkedIn identifies Aaron Boudreau as Senior Director, Target Biology at Scorpion Therapeutics in San Francisco. PubMed records show him as an author on multiple oncology and cancer-biology publications affiliated with Lawrence Berkeley National Laboratory, UCSF, and Genentech, which supports classification as a scientific ecosystem contributor rather than a capital deployer.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T04:20:01.628Z","updated_at":"2026-05-12T17:14:52.320Z","entities":[{"entity_name":"Scorpion Therapeutics","entity_type":"company","role":"Senior Director, Target Biology","url":"https://www.scorpiontx.com/"},{"entity_name":"Lawrence Berkeley National Laboratory","entity_type":"company","role":"research affiliate / author affiliation","url":"https://www.lbl.gov/"},{"entity_name":"University of California, San Francisco","entity_type":"company","role":"research affiliate / author affiliation","url":"https://www.ucsf.edu/"},{"entity_name":"Genentech","entity_type":"company","role":"research affiliate / author affiliation","url":"https://www.gene.com/"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/ztEgACtH","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"19aba0d3-8fd9-49fc-a39e-c4a83856dca4","public_id":"3eXexlMO","name":"Aaron Cravens","canonical_name":"aaron cravens","type":"individual","role":null,"bio":"Aaron Cravens is the co-founder and CEO of Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair age-related molecular damage. Before Revel, he worked at Google X and consulted for biotech companies. He holds a PhD in Bioengineering from Stanford University and has co-authored Nature Communications papers in synthetic biology and protein engineering.","url":null,"linkedin_url":"https://www.linkedin.com/in/aaron-cravens-61652162","twitter_handle":"aaroncravens5","x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/19aba0d3-8fd9-49fc-a39e-c4a83856dca4.webp","crunchbase_permalink":null,"sec_cik":null,"interests":["longevity","biotech","enzyme therapeutics","synthetic biology","protein engineering","aging repair therapies"],"connections":[{"name":"David Spiegel","relationship":"co-founded Revel Pharmaceuticals together"},{"name":"Jason Crawford","relationship":"co-founded Revel Pharmaceuticals together"},{"name":"Christina D. Smolke","relationship":"PhD advisor at Stanford and co-author"},{"name":"Patrick Burgermeister","relationship":"board colleague at Revel Pharmaceuticals"}],"source_urls":["https://revelpharmaceuticals.com/","https://www.biospace.com/kizoo-portfolio-company-revel-pharmaceuticals-announces-8-4m-seed-to-develop-repairing-based-approaches-to-reversing-aging","https://amaranth.foundation/","https://www.nature.com/articles/s41467-019-09848-w","https://www.nature.com/articles/s41467-021-21876-z","https://www.fightaging.org/archives/2020/01/revel-pharmaceuticals-finally-seed-funded-to-develop-glucosepane-cross-link-breakers/"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is for a real human being named Aaron Cravens, and the bio describes his personal career, education, and publications rather than a legal organization.","classified_at":"2026-07-02T22:00:52.689Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Amaranth Foundation identifies Cravens as CEO of Revel Pharmaceuticals and says he co-founded Revel in 2019 to develop repair-based therapies for aging. Nature Communications also lists him as an author on peer-reviewed synthetic biology and protein-engineering papers, supporting his role as a scientific/operator figure rather than a capital deployer.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, family-office control, foundation endowment, or verified personal net worth was found in reputable public sources. Public sources identify him as a biotech founder/operator and scientist rather than an investor.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Amaranth Foundation identifies Cravens as CEO of Revel Pharmaceuticals and says he co-founded Revel in 2019 to develop repair-based therapies for aging. Nature Communications also lists him as an author on peer-reviewed synthetic biology and protein-engineering papers, supporting his role as a scientific/operator figure rather than a capital deployer.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":"2026-08-01T10:10:04.286Z","dossier_last_refreshed_at":"2026-08-01T10:11:16.287Z","created_at":"2026-06-24T10:31:04.682Z","updated_at":"2026-08-10T21:36:26.634Z","entities":[{"entity_name":"Revel Pharmaceuticals","entity_type":"company","role":"CEO","url":"https://revelpharmaceuticals.com/"},{"entity_name":"Google X","entity_type":"company","role":"former employee","url":"https://x.company/"}],"labels":[],"funding_events_count":0,"public_content_count":122,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/3eXexlMO","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"ad21b290-650b-4ad7-a09c-a90c0acc3f98","public_id":"KxXt4VsU","name":"Aaron Ellenbogen","canonical_name":"aaron ellenbogen","type":"individual","role":null,"bio":"Aaron Ellenbogen, DO, MPH, FACN is a Michigan-based movement disorders neurologist focused on Parkinson's disease and related neurological conditions. He practices at the Michigan Institute for Neurological Disorders (MIND), serves as Medical Director at Quest Research Institute, and is active in clinical trials and academic teaching. He also serves as President of the Board of Directors and Chairman of the Professional Advisory Board at the Michigan Parkinson Foundation.","url":null,"linkedin_url":"https://www.linkedin.com/in/aaron-ellenbogen-do-mph-814887b5","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/ad21b290-650b-4ad7-a09c-a90c0acc3f98.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["Parkinson's disease","movement disorders","neurology","clinical research","medical education","restless legs syndrome","essential tremor","neurodegenerative disease"],"connections":[{"name":"Jeff Laethem","relationship":"board colleague at Michigan Parkinson Foundation"},{"name":"Kristin Rossi","relationship":"board colleague at Michigan Parkinson Foundation"},{"name":"Beth E. Safirstein","relationship":"coauthor on Parkinson's disease clinical research"}],"source_urls":["https://mindonline.com/doctors-staff/","https://mindonline.com/movement-disorders/","https://parkinsonsmi.org/about-us/","https://www.biospace.com/press-releases/neuron23-announces-96-5-million-series-d-financing-and-first-patient-dosed-in-global-phase-2-neulark-clinical-trial-of-neu-411-for-early-parkinsons-disease","https://pubmed.ncbi.nlm.nih.gov/32482490/","https://pubmed.ncbi.nlm.nih.gov/21242741/","https://www.linkedin.com/in/aaron-ellenbogen-do-mph-814887b5"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is a real individual because it uses a personal name, the type is 'individual,' and the bio describes Aaron Ellenbogen as a physician holding roles at multiple organizations rather than naming a legal entity.","classified_at":"2026-05-11T10:02:41.924Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] MIND identifies Aaron Ellenbogen as a movement disorders neurologist, researcher, assistant professor of medicine, and President of the Board of Directors/Chairman of the Professional Advisory Board at the Michigan Parkinson Foundation. BioSpace also identifies him as Medical Director at Quest Research Institute and a NEULARK study investigator.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, fund ownership, or equity-stake evidence was found in reputable public sources. Public sources identify him as a neurologist, clinical researcher, educator, and nonprofit board leader rather than an investor.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"MIND identifies Aaron Ellenbogen as a movement disorders neurologist, researcher, assistant professor of medicine, and President of the Board of Directors/Chairman of the Professional Advisory Board at the Michigan Parkinson Foundation. BioSpace also identifies him as Medical Director at Quest Research Institute and a NEULARK study investigator.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T03:05:01.278Z","updated_at":"2026-05-20T08:10:02.214Z","entities":[{"entity_name":"Michigan Institute for Neurological Disorders (MIND)","entity_type":"company","role":"neurologist","url":"https://mindonline.com/doctors-staff/"},{"entity_name":"Quest Research Institute","entity_type":"company","role":"medical director","url":"https://www.biospace.com/press-releases/neuron23-announces-96-5-million-series-d-financing-and-first-patient-dosed-in-global-phase-2-neulark-clinical-trial-of-neu-411-for-early-parkinsons-disease"},{"entity_name":"Michigan Parkinson Foundation","entity_type":"foundation","role":"president; chairman of professional advisory board","url":"https://parkinsonsmi.org/about-us/"},{"entity_name":"Oakland University William Beaumont School of Medicine","entity_type":"advisory","role":"assistant professor of medicine","url":"https://mindonline.com/doctors-staff/"},{"entity_name":"Ascension St. John Hospital","entity_type":"advisory","role":"core faculty member, neurology residency","url":"https://mindonline.com/doctors-staff/"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/KxXt4VsU","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"570011aa-36d6-45c0-be9a-bc680e09f8a9","public_id":"ynrzrn77","name":"Aaron Esser-Kahn","canonical_name":"aaron esser-kahn","type":"individual","role":null,"bio":"Aaron Esser-Kahn is a professor of molecular engineering at the University of Chicago whose work sits at the intersection of biology, chemistry, and materials science, with a strong focus on immunoengineering and vaccine response modulation. He previously worked at UC Irvine and has been recognized by the Illinois Science & Technology Coalition for translational research and invention activity. He also cofounded Signl, a preclinical biotech developing small-molecule approaches to tune immune responses.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/570011aa-36d6-45c0-be9a-bc680e09f8a9.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["biotech","immunoengineering","vaccines","cancer immunotherapy","materials science","molecular engineering","adaptive materials","bioengineering","medical technology","pandemic preparedness","quantum biology"],"connections":[{"name":"Jeremiah Kim","relationship":"co-founded Signl together"},{"name":"Saikat Manna","relationship":"worked together on the ChemImmune Polsky I-Corps team"}],"source_urls":["https://pme.uchicago.edu/directory/aaron-esser-kahn","https://polsky.uchicago.edu/2026/06/17/george-shultz-innovation-fund-awards-250k-to-parasol-medtech-and-signl/","https://pme.uchicago.edu/news-events/news/george-shultz-innovation-fund-awards-250k-uchicago-pme-founded-startup-signl","https://conferences.biocentury.com/grand-rounds-2024/speakers","https://arpa-h.gov/explore-funding/programs/circle/teaming","https://polsky.uchicago.edu/2020/11/17/11-teams-join-polskys-fall-2020-i-corps-program-cohort/","https://www.istcoalition.org/data/researchers-to-know-2022/","https://schools.cranbrook.edu/alumni/meet-our-alumni","https://www.signlbio.com/"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is a real human individual because it uses a personal name and multiple cited sources identify Aaron Esser-Kahn as a University of Chicago professor and startup cofounder rather than an organization.","classified_at":"2026-06-28T13:13:11.560Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] University of Chicago lists him as a Professor of Molecular Engineering whose research spans immunoengineering, materials, and bioengineering. BioCentury lists him as a 2024 speaker and its 2026 steering committee lists him as a scientific participant, indicating sector influence through research and convening rather than fund management.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"Reviewed public sources show Aaron Esser-Kahn as a University of Chicago professor, research inventor, ARPA-H teaming participant, and startup cofounder, but I found no reputable evidence of personal angel investing, fund ownership, disclosed equity stakes, or other documented personal capital deployment.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"University of Chicago lists him as a Professor of Molecular Engineering whose research spans immunoengineering, materials, and bioengineering. BioCentury lists him as a 2024 speaker and its 2026 steering committee lists him as a scientific participant, indicating sector influence through research and convening rather than fund management.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-06-23T18:20:38.884Z","updated_at":"2026-08-10T18:05:02.567Z","entities":[{"entity_name":"University of Chicago Pritzker School of Molecular Engineering","entity_type":"advisory","role":"professor","url":"https://pme.uchicago.edu/directory/aaron-esser-kahn"},{"entity_name":"Esser-Kahn Group","entity_type":"advisory","role":"principal investigator","url":"https://www.esser-kahnlab.org"},{"entity_name":"Signl","entity_type":"company","role":"cofounder","url":"https://www.signlbio.com/"},{"entity_name":"ChemImmune","entity_type":"company","role":"I-Corps team lead/member","url":"https://polsky.uchicago.edu/2020/11/17/11-teams-join-polskys-fall-2020-i-corps-program-cohort/"},{"entity_name":"BioCentury Grand Rounds","entity_type":"advisory","role":"speaker","url":"https://conferences.biocentury.com/grand-rounds-2024/speakers"},{"entity_name":"ARPA-H CIRCLE teaming","entity_type":"advisory","role":"teaming profile participant","url":"https://arpa-h.gov/explore-funding/programs/circle/teaming"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/ynrzrn77","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"4576c41f-1878-407e-9809-9eaef726694a","public_id":"Kv6PPa4V","name":"Aaron H Nile","canonical_name":null,"type":"individual","role":null,"bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row has a plausible human personal name and the prior `type` is `individual`, with no corporate suffixes or entity indicators present.","classified_at":"2026-05-11T11:50:06.613Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Aaron H. Nile appears in peer-reviewed biomedical publications as a scientist at Genentech and later Calico Life Sciences, indicating a research/knowledge role rather than a capital deployment role. For example, PubMed lists him as an author affiliated with Calico Life Sciences LLC and as corresponding author on a cancer-biology paper.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":"Aaron H. Nile appears in peer-reviewed biomedical publications as a scientist at Genentech and later Calico Life Sciences, indicating a research/knowledge role rather than a capital deployment role. For example, PubMed lists him as an author affiliated with Calico Life Sciences LLC and as corresponding author on a cancer-biology paper.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T04:20:01.644Z","updated_at":"2026-05-13T12:50:03.225Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/Kv6PPa4V","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"3938e7e9-6a50-48ec-874d-34a9276a1742","public_id":"XciAKYgp","name":"Aaron Hudson","canonical_name":"aaron hudson","type":"individual","role":null,"bio":"Aaron Hudson, PhD, is a biostatistician and assistant professor at Fred Hutchinson Cancer Center working across the Vaccine and Infectious Disease Division and Public Health Sciences Division. His research focuses on vaccine efficacy trials, immune-response analysis, causal inference, and high-dimensional statistical methods, including machine learning. He was also listed as a contributor at MIT's 2024 Conference on Digital Experimentation (CODE@MIT).","url":null,"linkedin_url":null,"twitter_handle":"@aaronwhudson","x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/3938e7e9-6a50-48ec-874d-34a9276a1742.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["biostatistics","vaccine development","infectious disease","public health","machine learning","causal inference","high-dimensional data","graphical models"],"connections":[{"name":"Wenxin Zhang","relationship":"co-author on a 2024 CODE@MIT presentation"},{"name":"Maya Petersen","relationship":"co-author on a 2024 CODE@MIT presentation"},{"name":"Mark van der Laan","relationship":"co-author on a 2024 CODE@MIT presentation"}],"source_urls":["https://www.fredhutch.org/en/faculty-lab-directory/hudson-aaron.html","https://ide.mit.edu/events/code24/"],"is_person":true,"person_tags":["key_employee"],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names Aaron Hudson as an individual, and the cited Fred Hutch faculty page identifies him as 'Aaron Hudson, PhD,' an assistant professor and biostatistician, which is a real human person rather than an organization.","classified_at":"2026-05-11T10:10:38.885Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Fred Hutch lists Aaron Hudson, PhD, as an Assistant Professor in the Vaccine and Infectious Disease Division and Public Health Sciences Division, focused on vaccine efficacy trials and machine-learning-based biostatistics. MIT's 2024 CODE conference also lists him as a Fred Hutch-affiliated presenter/co-author, supporting a research and knowledge-network role rather than a capital-deployment role.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, fund ownership, equity stake disclosures, or net-worth reporting was found in the available reputable sources.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Fred Hutch lists Aaron Hudson, PhD, as an Assistant Professor in the Vaccine and Infectious Disease Division and Public Health Sciences Division, focused on vaccine efficacy trials and machine-learning-based biostatistics. MIT's 2024 CODE conference also lists him as a Fred Hutch-affiliated presenter/co-author, supporting a research and knowledge-network role rather than a capital-deployment role.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T03:05:01.310Z","updated_at":"2026-06-28T17:20:15.950Z","entities":[{"entity_name":"Fred Hutchinson Cancer Center","entity_type":"company","role":"assistant professor","url":"https://www.fredhutch.org/en/faculty-lab-directory/hudson-aaron.html"},{"entity_name":"Public Health Sciences Division, Fred Hutch","entity_type":"advisory","role":"assistant professor","url":"https://www.fredhutch.org/en/faculty-lab-directory/hudson-aaron.html"},{"entity_name":"Vaccine and Infectious Disease Division, Fred Hutch","entity_type":"advisory","role":"assistant professor","url":"https://www.fredhutch.org/en/faculty-lab-directory/hudson-aaron.html"},{"entity_name":"Translational Data Science Integrated Research Center (TDS IRC)","entity_type":"advisory","role":"member","url":"https://www.fredhutch.org/en/faculty-lab-directory/hudson-aaron.html"},{"entity_name":"MIT Initiative on the Digital Economy (CODE@MIT 2024)","entity_type":"advisory","role":"conference presenter/co-author","url":"https://ide.mit.edu/events/code24/"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/XciAKYgp","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"37436da6-8258-430c-907e-b493bcf2d849","public_id":"Sw1Be5m2","name":"Aaron King","canonical_name":"aaron king","type":"individual","role":null,"bio":"Aaron King is the founder and executive chairman of Snapdocs, a digital mortgage-closing company in San Francisco. Snapdocs' official leadership page lists him as Founder & Executive Chairman, while Forbes identifies him as the founder/CEO of Snapdocs. Public funding records also show him participating as an angel investor in a small number of startup rounds, but no reputable source surfaced a verifiable personal-capital figure.","url":null,"linkedin_url":null,"twitter_handle":"a_aronking","x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/37436da6-8258-430c-907e-b493bcf2d849.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["fintech","mortgage technology","proptech","real estate","AI","enterprise software","productivity software"],"connections":[{"name":"Michael Sachdev","relationship":"leadership colleague at Snapdocs"},{"name":"Jawed Karim","relationship":"co-investor in Conduit's 2025 seed round"},{"name":"Bill Tai","relationship":"co-investor in Fathom's 2022 seed round"},{"name":"Frederic Kerrest","relationship":"co-investor in Trek Health's 2022 seed round"}],"source_urls":["https://www.crunchbase.com/person/aaron-king-2","https://www.snapdocs.com/meet-our-leadership-team","https://www.forbes.com/companies/snapdocs/","https://www.businesswire.com/news/home/20220124005098/en/Backed-by-Early-Zoom-Investors-Fathom-Launches-With-%244.7M-in-Seed-Funding","https://www.businesswire.com/news/home/20220909005467/en/Trek-Health-Raises-Oversubscribed-%242.7M-Seed-Round-to-Modernize-Mental-Health-Payments-Infrastructure","https://timesofindia.indiatimes.com/city/hyderabad/hyd-proptech-startup-landeed-raises-5-million/articleshow/117534264.cms","https://www.phocuswire.com/hostai-conduit-strs-artificial-intelligence-investment"],"is_person":true,"person_tags":["angel"],"entity_category":null,"classification_confidence":{"angel":0.82},"classification_reasoning":"This row represents a real human being because it is a personal name, the type is listed as individual, and the bio describes Aaron King as founder/executive chairman of Snapdocs with personal angel participation in startup rounds.","classified_at":"2026-05-09T04:33:01.567Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Snapdocs' official leadership page lists Aaron King as Founder & Executive Chairman, and Forbes' Snapdocs company profile identifies him as the company founder/CEO. That makes him a notable operator and network node in mortgage/proptech, not a formal fund manager.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"Crunchbase publicly lists Aaron King as an \"Individual/Angel\" investor with four personal investments, including Fathom, Trek Health, Landeed, and Conduit, but I did not find a reputable source establishing his personal net worth or a documented personal-capital figure; per your rule, this remains FALSE.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Snapdocs' official leadership page lists Aaron King as Founder & Executive Chairman, and Forbes' Snapdocs company profile identifies him as the company founder/CEO. That makes him a notable operator and network node in mortgage/proptech, not a formal fund manager.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":"2026-05-04T13:32:22.244Z","fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":"2026-06-07T19:08:25.828Z","dossier_last_refreshed_at":"2026-06-07T19:10:09.290Z","created_at":"2026-05-04T13:00:03.063Z","updated_at":"2026-06-09T22:30:02.515Z","entities":[{"entity_name":"Snapdocs","entity_type":"company","role":"founder & executive chairman","url":"https://www.snapdocs.com/meet-our-leadership-team"},{"entity_name":"Fathom","entity_type":"company","role":"investor","url":"https://www.businesswire.com/news/home/20220124005098/en/Backed-by-Early-Zoom-Investors-Fathom-Launches-With-%244.7M-in-Seed-Funding"},{"entity_name":"Trek Health","entity_type":"company","role":"investor","url":"https://www.businesswire.com/news/home/20220909005467/en/Trek-Health-Raises-Oversubscribed-%242.7M-Seed-Round-to-Modernize-Mental-Health-Payments-Infrastructure"},{"entity_name":"Landeed","entity_type":"company","role":"investor","url":"https://timesofindia.indiatimes.com/city/hyderabad/hyd-proptech-startup-landeed-raises-5-million/articleshow/117534264.cms"},{"entity_name":"Conduit","entity_type":"company","role":"investor","url":"https://www.phocuswire.com/hostai-conduit-strs-artificial-intelligence-investment"}],"labels":[],"funding_events_count":4,"public_content_count":140,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/Sw1Be5m2","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"e615434a-6d5f-4d8e-bb47-995aa8dc0612","public_id":"o2Ubdlpu","name":"Aaron Leifer","canonical_name":null,"type":"individual","role":null,"bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is a plain personal name with no corporate markers, and the prior `type` field is `individual`, with no conflicting evidence in any other field.","classified_at":"2026-05-10T17:22:31.569Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Point Foundation lists Aaron P. Leifer as Co-Vice Chair of its Board of Directors, and SFMTA lists him as Chair of its Citizens' Advisory Council. These are governance/network roles that fit ecosystem influence rather than primary capital deployment.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No reputable source found documenting Aaron Leifer's personal wealth, angel investing, family-office/foundation principal status, or equity stakes. The available official biographies describe him as a retired AT&T communications/consulting professional and nonprofit supporter, not a capital owner.","evidence_fund_operator":"No evidence found that Aaron Leifer holds a paid management or investment role at a fund, family office, foundation, or other capital-managing institution. His documented roles are nonprofit board and public advisory positions rather than fund operations.","evidence_ecosystem_influencer":"Point Foundation lists Aaron P. Leifer as Co-Vice Chair of its Board of Directors, and SFMTA lists him as Chair of its Citizens' Advisory Council. These are governance/network roles that fit ecosystem influence rather than primary capital deployment.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T04:20:01.649Z","updated_at":"2026-09-18T10:50:07.961Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/o2Ubdlpu","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"20f93f88-462b-4adb-91c3-930c9b9d5f19","public_id":"yUHTJGFC","name":"Aaron M Cypess","canonical_name":null,"type":"individual","role":null,"bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The name is a real personal name with no corporate or organizational suffix, and the prior `type` field also indicates `individual`.","classified_at":"2026-05-11T11:50:52.816Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Aaron M. Cypess is a biomedical scientist and Section Chief of the Translational Physiology Section at the NIH's NIDDK, with a research profile focused on obesity and brown adipose tissue rather than capital deployment. NIH and PubMed sources document him as a senior researcher/author, which fits ecosystem influence through scientific expertise and research leadership.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":"Aaron M. Cypess is a biomedical scientist and Section Chief of the Translational Physiology Section at the NIH's NIDDK, with a research profile focused on obesity and brown adipose tissue rather than capital deployment. NIH and PubMed sources document him as a senior researcher/author, which fits ecosystem influence through scientific expertise and research leadership.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T04:20:01.655Z","updated_at":"2026-05-12T15:40:07.381Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/yUHTJGFC","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"fa8b4d11-3334-448f-95ea-3803a7e97bc9","public_id":"fd5IXdQj","name":"Aaron M. Cypess","canonical_name":"aaron cypess","type":"individual","role":"private_investor","bio":"Aaron M. Cypess is an NIH physician-scientist focused on brown adipose tissue, obesity, diabetes, and metabolic physiology. He serves as Section Chief of the Translational Physiology Section within NIDDK's Diabetes, Endocrinology, & Obesity Branch. Earlier in his career, he was on the faculty at Harvard Medical School and held clinical/research roles at Joslin Diabetes Center and Beth Israel Deaconess Medical Center.","url":null,"linkedin_url":null,"twitter_handle":"acypess","x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/fa8b4d11-3334-448f-95ea-3803a7e97bc9.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["biotech","obesity","diabetes","endocrinology","metabolism","brown adipose tissue","clinical research","metabolic imaging","therapeutics","cardiometabolic disease","PCOS"],"connections":[{"name":"Marc Reitman","relationship":"co-chairs the NIH Metabolism Interest Group with Cypess listed as a contact/co-chair"},{"name":"Jürgen Wess","relationship":"co-chairs/advises the NIH Metabolism Interest Group alongside Cypess"},{"name":"C. Ronald Kahn","relationship":"co-authored the 2009 NEJM paper on brown adipose tissue with Cypess"}],"source_urls":["https://www.niddk.nih.gov/about-niddk/staff-directory/biography/cypess-aaron","https://www.niddk.nih.gov/research-funding/at-niddk/labs-branches/diabetes-endocrinology-obesity-branch","https://www.niddk.nih.gov/research-funding/at-niddk/faculty","https://oir.nih.gov/sigs/metabolism-interest-group","https://www.nih.gov/news-events/news-releases/drug-increases-brown-fat-activity-healthy-women","https://pubmed.ncbi.nlm.nih.gov/19357406/"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is for a named individual with an NIH/academic physician-scientist biography and no organizational suffixes or entity indicators.","classified_at":"2026-05-11T12:02:43.872Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] NIDDK identifies Cypess as Section Chief of the Translational Physiology Section in the Diabetes, Endocrinology, & Obesity Branch, and NIH describes him as leading brown-fat and metabolic-disease research. The NIH Office of Intramural Research also lists him as a chair/advisor of the Metabolism Interest Group, indicating scientific-network influence rather than capital deployment.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, family-office principal role, or disclosed equity stakes were found in reviewed sources. Official NIH/NIDDK materials present him as a physician-scientist and section chief rather than an investor.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"NIDDK identifies Cypess as Section Chief of the Translational Physiology Section in the Diabetes, Endocrinology, & Obesity Branch, and NIH describes him as leading brown-fat and metabolic-disease research. The NIH Office of Intramural Research also lists him as a chair/advisor of the Metabolism Interest Group, indicating scientific-network influence rather than capital deployment.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":"2026-06-26T16:00:55.345Z","dossier_last_refreshed_at":"2026-06-26T16:06:59.484Z","created_at":"2026-05-11T11:41:02.532Z","updated_at":"2026-06-26T16:06:59.484Z","entities":[{"entity_name":"National Institute of Diabetes and Digestive and Kidney Diseases","entity_type":"advisory","role":"section chief","url":"https://www.niddk.nih.gov/about-niddk/staff-directory/biography/cypess-aaron"},{"entity_name":"National Institutes of Health","entity_type":"advisory","role":"investigator","url":"https://www.nih.gov/"},{"entity_name":"Diabetes, Endocrinology, & Obesity Branch","entity_type":"advisory","role":"section chief","url":"https://www.niddk.nih.gov/research-funding/at-niddk/labs-branches/diabetes-endocrinology-obesity-branch"},{"entity_name":"Metabolism Interest Group","entity_type":"advisory","role":"chair and advisor","url":"https://oir.nih.gov/sigs/metabolism-interest-group"},{"entity_name":"Harvard Medical School","entity_type":"company","role":"assistant professor of medicine","url":"https://www.niddk.nih.gov/about-niddk/staff-directory/biography/cypess-aaron"},{"entity_name":"Joslin Diabetes Center","entity_type":"company","role":"assistant investigator and staff physician","url":"https://www.niddk.nih.gov/about-niddk/staff-directory/biography/cypess-aaron"},{"entity_name":"Beth Israel Deaconess Medical Center","entity_type":"company","role":"staff physician","url":"https://www.niddk.nih.gov/about-niddk/staff-directory/biography/cypess-aaron"},{"entity_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","entity_type":"company","role":"section chief","url":"https://www.niddk.nih.gov/about-niddk/staff-directory/biography/cypess-aaron"},{"entity_name":"National Institutes of Health (NIH)","entity_type":"company","role":"senior physician-scientist","url":"https://www.nih.gov/news-events/news-releases/drug-increases-brown-fat-activity-healthy-women"},{"entity_name":"Translational Physiology Section","entity_type":"advisory","role":"section chief","url":"https://www.niddk.nih.gov/research-funding/at-niddk/labs-branches/diabetes-endocrinology-obesity-branch"},{"entity_name":"NIH Metabolism Interest Group","entity_type":"advisory","role":"chair and advisor","url":"https://oir.nih.gov/sigs/metabolism-interest-group"}],"labels":[],"funding_events_count":0,"public_content_count":64,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/fd5IXdQj","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"208119f3-64da-4f3b-8202-788d0bce6727","public_id":"AUYGdbqW","name":"Aaron Mitchell-Dick","canonical_name":"aaron mitchell-dick","type":"individual","role":null,"bio":"Aaron Mitchell-Dick is a biomedical scientist with a Duke University research background spanning neuroscience, gene therapy, AAV vector engineering, and CRISPR-based RNA technologies. Duke-linked sources show he completed his PhD at Duke, published across neuroscience and gene-therapy topics, and by 2024 was listed as Scientist II at 4D Molecular Therapeutics. Retro Biosciences' team page also lists him among its current team members, connecting him to a longevity-focused biotech environment.","url":null,"linkedin_url":"https://www.linkedin.com/in/aaron-mitchell-dick","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/208119f3-64da-4f3b-8202-788d0bce6727.png","crunchbase_permalink":null,"sec_cik":null,"interests":["gene therapy","AAV vectors","CRISPR/RNA editing","neuroscience","biotech","longevity"],"connections":[{"name":"Aravind Asokan","relationship":"Duke collaborator and senior co-author on gene-therapy publications"},{"name":"Chay T. Kuo","relationship":"Duke advisor on a Broad Foundation graduate student award listing"}],"source_urls":["https://www.asokanlab.org/about-us","https://sites.duke.edu/silverlab/people/lab-alumni/","https://sites.duke.edu/silverlab/lab-news/","https://sites.duke.edu/broadfoundation/intramural-grant-recipients/graduate-student-grant-awardees/","https://pubmed.ncbi.nlm.nih.gov/38485709/","https://pubmed.ncbi.nlm.nih.gov/29495257/","https://pubmed.ncbi.nlm.nih.gov/27047330/","https://www.retro.bio/team","https://www.linkedin.com/in/aaron-mitchell-dick"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names a specific individual and the supporting evidence describes his academic and industry employment history rather than any company, fund, or other legal entity.","classified_at":"2026-05-11T07:30:09.548Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Public sources identify Mitchell-Dick as a Duke-trained scientist and author on gene-therapy and neuroscience publications, including a 2024 Nature Communications paper on CRISPR-Cas13 mRNA trans-splicing and Duke-affiliated work on AAV gene delivery. Duke and lab alumni pages also list him as a PhD alumnus who became Scientist II at 4D Molecular Therapeutics, indicating a research-facing role rather than a capital-deployment role.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, board-seat equity stake, or reported net worth was found in the available public sources.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Public sources identify Mitchell-Dick as a Duke-trained scientist and author on gene-therapy and neuroscience publications, including a 2024 Nature Communications paper on CRISPR-Cas13 mRNA trans-splicing and Duke-affiliated work on AAV gene delivery. Duke and lab alumni pages also list him as a PhD alumnus who became Scientist II at 4D Molecular Therapeutics, indicating a research-facing role rather than a capital-deployment role.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-05T15:13:14.825Z","updated_at":"2026-05-12T16:36:19.700Z","entities":[{"entity_name":"4D Molecular Therapeutics","entity_type":"company","role":"Scientist II","url":"https://www.linkedin.com/in/aaron-mitchell-dick"},{"entity_name":"Retro Biosciences","entity_type":"company","role":"team member","url":"https://www.retro.bio/team"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/AUYGdbqW","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"05c39be7-bbed-452e-a813-47e05496157f","public_id":"O37bMlCb","name":"Aaron Nelson MD, PhD","canonical_name":null,"type":"individual","role":"private_investor","bio":"Aaron Nelson MD, PhD is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to NVF, he was an investor at dRx Capital.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":["https://www.nvfund.com/team/aaron-nelson"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names a real human individual and the cited Novartis Venture Fund team page describes Aaron Nelson MD, PhD as a Managing Director, not as an organization.","classified_at":"2026-05-05T05:20:22.466Z","role_kind":"fund_operator","role_kind_evidence":"[operator] Novartis Venture Fund's official team page identifies Aaron Nelson, MD, PhD as a Managing Director in Cambridge, MA, and states that he was previously an investor at dRx Capital. A Managing Director at a venture fund is a paid investment-management role, which meets the fund-operator definition. Source: https://www.nvfund.com/team/aaron-nelson","is_capital_owner":false,"is_fund_operator":true,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":"Novartis Venture Fund's official team page identifies Aaron Nelson, MD, PhD as a Managing Director in Cambridge, MA, and states that he was previously an investor at dRx Capital. A Managing Director at a venture fund is a paid investment-management role, which meets the fund-operator definition. Source: https://www.nvfund.com/team/aaron-nelson","evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":"Aaron Nelson is an individual, and the schema specifies that fund_aum is for funds/institutions only, so this field should be null even though he works at a venture fund.","net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"stub","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-29T01:53:31.616Z","updated_at":"2026-05-12T00:08:17.503Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/O37bMlCb","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"8692a041-8df5-4c75-86e3-c02a53df25db","public_id":"COKiR7HA","name":"Aaron Nelson, MD, PhD","canonical_name":"aaron nelson","type":"corporate_vc","role":"private_investor","bio":"Aaron Nelson, MD, PhD is a biotech and life sciences investor currently serving as Partner at Novo Holdings in the US venture investments team. He previously was a Managing Director at Novartis Venture Fund, where he led Seed and Series A therapeutic drug discovery investments, and earlier was an investor at dRx Capital, the Novartis-Qualcomm digital medicine investment vehicle. Before investing, he held R&D and strategy roles inside Novartis and trained academically at Cornell, the University of Pennsylvania, Karolinska Institutet, and Tufts.","url":null,"linkedin_url":"https://www.linkedin.com/in/aaron-nelson-a021388/","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/8692a041-8df5-4c75-86e3-c02a53df25db.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["biotech","therapeutics","drug discovery","genomic medicine","cell therapy","oncology","digital health","clinical trials","healthcare data","life sciences"],"connections":[{"name":"Henry Chen","relationship":"co-investor and board colleague in Exsilio Therapeutics' Series A financing"},{"name":"Tom Cahill","relationship":"board colleague at Exo Therapeutics"},{"name":"Lucian Iancovici","relationship":"co-general partner at dRx Capital"}],"source_urls":["https://novoholdings.dk/people/aaron-nelson","https://www.nvfund.com/team/aaron-nelson","https://ilp.mit.edu/attend/2016-mit-digital-health-conference","https://www.prnewswire.com/news-releases/exsilio-therapeutics-launches-with-82-million-series-a-financing-to-develop-redosable-genomic-medicines-for-a-broad-range-of-diseases-302179289.html","https://www.prnewswire.com/news-releases/immpact-bio-usa-inc-raises-18-million-in-series-a-financing-301113520.html","https://immpact-bio.com/news-and-events/immpact-bio-closes-111-million-series-b-financing-names-new-board-chair-and-new-president-and-ceo-and-updates-on-phase-1-clinical-study-in-relapsed-refractory-b-cell-non-hodgkins-lymphoma/","https://exo-therapeutics.com/wp-content/uploads/2020/12/pr-12-16-2020-Exo-Therapeutics-Series-A.pdf","https://exo-therapeutics.com/wp-content/uploads/2021/10/pr-10-05-2021-Exo-Therapeutics-Raises-Series-B_Financing.pdf","https://www.prnewswire.com/news-releases/science-37-secures-65m-series-a-funding-to-accelerate-clinical-trial-research-300162614.html","https://www.prnewswire.com/news-releases/science-37-secures-31m-series-b-funding-to-expand-clinical-trial-access-to-anyone-anywhere-anytime-300346363.html"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is a real human individual, evidenced by the personal name with academic credentials and a bio describing his employment history and roles at investment firms rather than a legal organization.","classified_at":"2026-05-10T22:43:57.286Z","role_kind":"fund_operator","role_kind_evidence":"[operator] Novo Holdings' official people page identifies Aaron Nelson as a Partner in Venture Investments, Novo Holdings US Inc., joining in June 2025. Novartis Venture Fund's official team page previously listed him as a Managing Director and names multiple portfolio companies he oversaw.","is_capital_owner":false,"is_fund_operator":true,"is_ecosystem_influencer":false,"evidence_capital_owner":"No reputable source found documenting personal angel investing, personal net worth, family-office/foundation principal status, or personal equity stakes deployed in his own name.","evidence_fund_operator":"Novo Holdings' official people page identifies Aaron Nelson as a Partner in Venture Investments, Novo Holdings US Inc., joining in June 2025. Novartis Venture Fund's official team page previously listed him as a Managing Director and names multiple portfolio companies he oversaw.","evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-05T05:12:59.835Z","updated_at":"2026-05-12T11:25:43.375Z","entities":[{"entity_name":"Novo Holdings","entity_type":"fund","role":"partner","url":"https://novoholdings.dk/people/aaron-nelson"},{"entity_name":"ImmPACT Bio","entity_type":"company","role":"observer","url":"https://www.nvfund.com/team/aaron-nelson"},{"entity_name":"Novartis Venture Fund","entity_type":"fund","role":"managing director","url":"https://www.nvfund.com/team/aaron-nelson"},{"entity_name":"Redona Therapeutics","entity_type":"company","role":"board observer","url":"https://www.nvfund.com/team/aaron-nelson"},{"entity_name":"dRx Capital","entity_type":"fund","role":"general partner","url":"https://ilp.mit.edu/attend/2016-mit-digital-health-conference"},{"entity_name":"Arvada Therapeutics","entity_type":"company","role":"board director","url":"https://www.nvfund.com/team/aaron-nelson"},{"entity_name":"Exo Therapeutics","entity_type":"company","role":"board director","url":"https://www.nvfund.com/team/aaron-nelson"},{"entity_name":"Averna Therapeutics","entity_type":"company","role":"board director","url":"https://www.nvfund.com/team/aaron-nelson"},{"entity_name":"Novartis","entity_type":"company","role":"R&D and strategy roles","url":"https://novoholdings.dk/people/aaron-nelson"},{"entity_name":"ImmPACT-Bio","entity_type":"company","role":"board observer","url":"https://www.nvfund.com/team/aaron-nelson"},{"entity_name":"Exsilio Therapeutics","entity_type":"company","role":"board member","url":"https://www.prnewswire.com/news-releases/exsilio-therapeutics-launches-with-82-million-series-a-financing-to-develop-redosable-genomic-medicines-for-a-broad-range-of-diseases-302179289.html"}],"labels":[],"funding_events_count":8,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/COKiR7HA","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"ef297a47-b32e-44da-b5e9-b5abae901429","public_id":"BPgTyMLR","name":"Aaron Nile","canonical_name":"aaron nile","type":"individual","role":null,"bio":"Aaron Nile is a scientist in oncology drug discovery associated with Calico Life Sciences. Public materials describe his work as combining biochemistry, structural biology, and computing to support therapeutic discovery. He has also appeared in QB3-Berkeley programming as a Professional in Residence, suggesting a broader mentorship and ecosystem-facing role in biotech.","url":null,"linkedin_url":"https://www.linkedin.com/in/aaronnile","twitter_handle":"aaron_nile","x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/ef297a47-b32e-44da-b5e9-b5abae901429.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["oncology","biotech","drug discovery","biochemistry","structural biology","computing","therapeutics","degraders","bioactive peptides","small molecules","antibodies","covalent technologies","Wnt signaling","E3 ligase biology","HPV-related cancer biology"],"connections":[{"name":"Bradley L. Pentelute","relationship":"research collaborator and co-corresponding author on peptide therapeutics papers with MIT"},{"name":"John C. K. Wang","relationship":"Calico colleague and coauthor on HPV-related research"},{"name":"Dan L. Eaton","relationship":"Calico colleague and coauthor on Calico oncology publications"}],"source_urls":["https://calicolabs.com/people/aaron-nile","https://qb3.berkeley.edu/news/professional-in-residence-interview-seth-lieblich/","https://qb3.berkeley.edu/research-news/crispr-researchers-and-startup-entrepreneurs-will-share-new-building-in-uc-berkeleys-innovation-zone/","https://www.linkedin.com/in/aaronnile"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is a real individual person: it has a personal name, `type: individual`, and the bio/LinkedIn-style sources describe Aaron Nile as a scientist and mentor rather than a legal entity.","classified_at":"2026-06-24T03:02:12.683Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Calico Life Sciences publicly identifies Aaron Nile as a Principal Investigator in Oncology focused on drug discovery at the intersection of biochemistry, structural biology, and computing. QB3-Berkeley also featured him as a Professional in Residence for biotech career programming, indicating a scientific and mentorship role rather than a capital-deployment role.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, family-office principal role, foundation endowment role, or disclosed equity stake holdings were found in the available public sources reviewed.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Calico Life Sciences publicly identifies Aaron Nile as a Principal Investigator in Oncology focused on drug discovery at the intersection of biochemistry, structural biology, and computing. QB3-Berkeley also featured him as a Professional in Residence for biotech career programming, indicating a scientific and mentorship role rather than a capital-deployment role.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":"2026-08-06T05:12:50.582Z","dossier_last_refreshed_at":"2026-08-06T05:20:31.947Z","created_at":"2026-05-07T00:30:31.082Z","updated_at":"2026-08-06T15:50:02.949Z","entities":[{"entity_name":"Calico Life Sciences","entity_type":"company","role":"principal investigator","url":"https://calicolabs.com/people/aaron-nile"},{"entity_name":"Genentech","entity_type":"company","role":"postdoctoral researcher","url":"https://www.calicolabs.com/people/aaron-nile-ph-d/"},{"entity_name":"QB3 Berkeley","entity_type":"advisory","role":"Professional in Residence","url":"https://qb3.berkeley.edu/education/career-development/pir/"},{"entity_name":"University of North Carolina at Chapel Hill","entity_type":"advisory","role":"ph.d. alumnus","url":"https://www.calicolabs.com/people/aaron-nile-ph-d/"},{"entity_name":"The Ohio State University","entity_type":"advisory","role":"b.s. alumnus","url":"https://www.calicolabs.com/people/aaron-nile-ph-d/"},{"entity_name":"QB3-Berkeley","entity_type":"advisory","role":"professional in residence","url":"https://qb3.berkeley.edu/news/exploring-careers-in-biotech-with-professional-in-residence-aaron-nile/"}],"labels":[],"funding_events_count":0,"public_content_count":144,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/BPgTyMLR","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"768a3664-ef7a-46ca-afc9-f6ab6b3d7bda","public_id":"rycCyewh","name":"Aaron Nile, Ph.D.","canonical_name":null,"type":"individual","role":null,"bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The name is formatted as a real personal name with an academic suffix ('Ph.D.') and there are no corporate or organizational indicators, while the prior `type` field also says `individual`.","classified_at":"2026-05-13T08:56:22.845Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Calico identifies Aaron Nile, Ph.D. as a Principal Investigator focused on oncology drug discovery, which fits a scientific/knowledge-network role rather than a capital-deploying one. QB3 Berkeley also lists him as a Professional in Residence giving career talks and mentoring, reinforcing ecosystem influence through research and guidance.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":"Calico identifies Aaron Nile, Ph.D. as a Principal Investigator focused on oncology drug discovery, which fits a scientific/knowledge-network role rather than a capital-deploying one. QB3 Berkeley also lists him as a Professional in Residence giving career talks and mentoring, reinforcing ecosystem influence through research and guidance.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T01:53:29.082Z","updated_at":"2026-05-13T08:56:22.845Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/rycCyewh","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"93b5cc05-cb27-4a5f-874d-bf82f7890317","public_id":"LTcxiSHH","name":"Aaron P. Leifer","canonical_name":"aaron leifer","type":"individual","role":"private_investor","bio":"Aaron P. Leifer is a San Francisco-based nonprofit board leader and civic advisor. Point Foundation lists him as Co-Vice Chair of its Board of Directors, and SFMTA lists him as Chair of its Citizens' Advisory Council. Point Foundation says he retired from AT&T, where he had been an Associate Director of Technical Consulting, and that he graduated cum laude from UC Irvine with a degree in psychology.","url":null,"linkedin_url":"https://www.linkedin.com/in/apleifer","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/93b5cc05-cb27-4a5f-874d-bf82f7890317.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["LGBTQ+ education","scholarships","nonprofit governance","public transportation","civic engagement","knowledge management","technical communications","community affairs"],"connections":[{"name":"Chris Arvin","relationship":"vice chair colleague on the SFMTA Citizens' Advisory Council"},{"name":"Peter Lichtenthal","relationship":"board colleague at Point Foundation"},{"name":"Marnie Merriam","relationship":"co-vice chair colleague at Point Foundation"}],"source_urls":["https://pointfoundation.org/about/boards-committees","https://www.sfmta.com/node/2631","https://www.linkedin.com/in/apleifer"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is a real individual because it uses a personal name, the type is listed as individual, and the bio describes his personal career and nonprofit board service rather than any legal entity.","classified_at":"2026-05-11T03:51:33.663Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Point Foundation lists Aaron P. Leifer as Co-Vice Chair of its Board of Directors, a governance role at a major LGBTQ+ scholarship nonprofit. SFMTA lists him as Chair of its Citizens' Advisory Council, an advisory body to the agency's Board of Directors.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, family-office principal role, foundation endowment role, or disclosed equity stakes were found in the available public sources. The public record located centers on nonprofit board service, civic advisory roles, and a prior AT&T career rather than investing activity.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Point Foundation lists Aaron P. Leifer as Co-Vice Chair of its Board of Directors, a governance role at a major LGBTQ+ scholarship nonprofit. SFMTA lists him as Chair of its Citizens' Advisory Council, an advisory body to the agency's Board of Directors.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-10T17:16:25.722Z","updated_at":"2026-05-12T12:41:29.252Z","entities":[{"entity_name":"San Francisco Municipal Transportation Agency","entity_type":"advisory","role":"chair","url":"https://www.sfmta.com/node/2631"},{"entity_name":"University of California, Irvine","entity_type":"advisory","role":"alumnus","url":"https://pointfoundation.org/about/boards-committees"},{"entity_name":"Point Foundation","entity_type":"foundation","role":"board member","url":"https://pointfoundation.org/about/boards-committees"},{"entity_name":"San Francisco Municipal Transportation Agency Citizens' Advisory Council","entity_type":"advisory","role":"chair","url":"https://www.sfmta.com/node/2631"},{"entity_name":"AT&T","entity_type":"company","role":"associate director","url":"https://www.linkedin.com/in/apleifer"},{"entity_name":"Regional Network Management Customer Advisory Group","entity_type":"advisory","role":"member representing SFMTA","url":"https://mtc.ca.gov/about-mtc/committees/interagency-committees/regional-network-management-customer-advisory-group"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/LTcxiSHH","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"7fbc088a-9d7a-4dd5-bbae-b3fda0ee208c","public_id":"EsXAJaPT","name":"Aaron Rapaport","canonical_name":"aaron rapaport","type":"individual","role":null,"bio":"Aaron Rapaport is an immunology scientist working in longevity-focused biotech. Deciduous Therapeutics lists him as Principal Scientist and says he previously worked at Genentech and trained at Amgen. His earlier academic work includes a Ph.D. in immunology from Washington University in St. Louis and multiple peer-reviewed publications in immunology and cancer biology.","url":null,"linkedin_url":"https://www.linkedin.com/in/aaron-rapaport-907864204","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/7fbc088a-9d7a-4dd5-bbae-b3fda0ee208c.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["longevity","biotech","immunology","autoimmunity","cancer immunotherapy","aging research","senescence"],"connections":[{"name":"Wenjun Ouyang","relationship":"co-authored immunology publications with Rapaport at Amgen"},{"name":"Robin Mansukhani","relationship":"colleague at Deciduous Therapeutics"},{"name":"Linda Lee","relationship":"joined Deciduous Therapeutics alongside Rapaport in a team announcement"}],"source_urls":["https://www.deciduoustx.com/about-us/","https://www.linkedin.com/company/deciduous-therapeutics","https://www.linkedin.com/in/aaron-rapaport-907864204","https://openscholarship.wustl.edu/etd/1338/","https://pubmed.ncbi.nlm.nih.gov/29945999/","https://pmc.ncbi.nlm.nih.gov/articles/PMC4745883/","https://pmc.ncbi.nlm.nih.gov/articles/PMC10897541/"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names a real individual and the bio describes Aaron Rapaport as a scientist with employment, education, and publication history rather than a legal entity.","classified_at":"2026-05-13T08:36:38.516Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Deciduous Therapeutics identifies Aaron Rapaport as a Principal Scientist with expertise in immunology, autoimmunity, and cancer immunotherapy. His Washington University dissertation and PubMed/PMC publication record show a research career in immunology spanning Washington University, Amgen, and Genentech, which fits the research/scientific-influencer category rather than capital deployment.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, board-seat equity stakes, family-office role, or net-worth reporting was found in reputable public sources. The public record located for this Aaron Rapaport is scientific and operating work, not investing.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Deciduous Therapeutics identifies Aaron Rapaport as a Principal Scientist with expertise in immunology, autoimmunity, and cancer immunotherapy. His Washington University dissertation and PubMed/PMC publication record show a research career in immunology spanning Washington University, Amgen, and Genentech, which fits the research/scientific-influencer category rather than capital deployment.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-07T01:20:11.804Z","updated_at":"2026-05-13T12:50:05.100Z","entities":[{"entity_name":"Genentech","entity_type":"company","role":"scientist","url":"https://www.deciduoustx.com/about-us/"},{"entity_name":"Amgen","entity_type":"company","role":"postdoctoral researcher / scientist","url":"https://pubmed.ncbi.nlm.nih.gov/29945999/"},{"entity_name":"Deciduous Therapeutics","entity_type":"company","role":"principal scientist","url":"https://www.deciduoustx.com/about-us/"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/EsXAJaPT","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"720837a5-6ba6-4b85-b97e-a894d4337a33","public_id":"ANBVYyWx","name":"Aaron Richard Hansen","canonical_name":"aaron hansen","type":"individual","role":null,"bio":"Aaron Richard Hansen is a Canadian-based medical oncologist and clinician-scientist at Princess Margaret Cancer Centre, University Health Network, and an Associate Professor of Medicine at the University of Toronto. His work focuses on head and neck cancers, genitourinary tumors, experimental therapeutics, immunotherapy, and patient-reported outcomes in early-phase clinical trials. He also holds national trial-network roles including CCTG Head and Neck Committee Co-Chair and participation on NCI recurrent metastatic head and neck cancer committees.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/720837a5-6ba6-4b85-b97e-a894d4337a33.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["oncology","immunotherapy","experimental therapeutics","clinical trials","drug development","head and neck cancer","genitourinary cancer","patient-reported outcomes","health-related quality of life"],"connections":[{"name":"Lillian Siu","relationship":"colleague on the Princess Margaret Phase I Program"},{"name":"Philippe Bedard","relationship":"colleague on the Princess Margaret Phase I Program"},{"name":"Anna Spreafico","relationship":"colleague on the Princess Margaret Phase I Program"},{"name":"Albiruni Razak","relationship":"colleague on the Princess Margaret Phase I Program"}],"source_urls":["https://www.ctg.queensu.ca/public/dr-aaron-hansen-bsc-mbbs-fracp","https://brasddp.com/about-us/medical-team/dr-aaron-hansen/","https://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Medical_Oncology_Hematology/Pages/research.aspx","https://www.uhn.ca/PrincessMargaret/Documents/Princess_Margaret_annual_report_2015.pdf","https://deptmedicine.utoronto.ca/division-medical-oncology-awards"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names Aaron Richard Hansen as an individual, and the cited sources describe Dr. Aaron Hansen as a staff medical oncologist and University of Toronto faculty member, which clearly identifies a real human rather than an organization.","classified_at":"2026-05-15T08:32:40.977Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Canadian Cancer Trials Group identifies Hansen as a staff medical oncologist at Princess Margaret Cancer Centre, Associate Professor of Medicine at the University of Toronto, CCTG Head and Neck Committee Co-Chair, and principal investigator on phase I-III trials. BRAS Drug Development Program materials further describe him as GU medical oncology site lead and a researcher focused on new anticancer therapies, HRQOL, and patient-reported outcomes.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, equity-stake ownership, family-office role, or foundation-principal status was found in the public sources reviewed. The available evidence identifies him as an academic medical oncologist and clinician-scientist rather than an investor.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Canadian Cancer Trials Group identifies Hansen as a staff medical oncologist at Princess Margaret Cancer Centre, Associate Professor of Medicine at the University of Toronto, CCTG Head and Neck Committee Co-Chair, and principal investigator on phase I-III trials. BRAS Drug Development Program materials further describe him as GU medical oncology site lead and a researcher focused on new anticancer therapies, HRQOL, and patient-reported outcomes.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":"2026-06-11T22:40:45.062Z","dossier_last_refreshed_at":"2026-06-11T22:46:40.060Z","created_at":"2026-05-06T03:05:01.325Z","updated_at":"2026-06-11T22:46:40.060Z","entities":[{"entity_name":"Princess Margaret Cancer Centre","entity_type":"company","role":"staff medical oncologist; genitourinary medical oncology site lead","url":"https://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Medical_Oncology_Hematology/Pages/research.aspx"},{"entity_name":"University Health Network","entity_type":"company","role":"staff physician","url":"https://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Medical_Oncology_Hematology/Pages/research.aspx"},{"entity_name":"University of Toronto","entity_type":"advisory","role":"associate professor of medicine","url":"https://www.ctg.queensu.ca/public/dr-aaron-hansen-bsc-mbbs-fracp"},{"entity_name":"Canadian Cancer Trials Group","entity_type":"advisory","role":"Head and Neck Committee Co-Chair; member of QOL and IND committees","url":"https://www.ctg.queensu.ca/public/dr-aaron-hansen-bsc-mbbs-fracp"},{"entity_name":"BRAS Drug Development Program","entity_type":"advisory","role":"clinical research fellow alumnus; medical team member","url":"https://brasddp.com/about-us/medical-team/dr-aaron-hansen/"}],"labels":[],"funding_events_count":0,"public_content_count":38,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/ANBVYyWx","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"b45fd58a-7b17-4093-acec-08f8d175afce","public_id":"2DCqvykQ","name":"Aaron S Meyer","canonical_name":null,"type":"individual","role":null,"bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row has a real personal name with no corporate markers and the prior `type` field is `individual`, with no contrary evidence in any other field.","classified_at":"2026-05-10T12:36:01.257Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] UCLA Profiles lists Aaron S Meyer as an Associate Professor of Bioengineering, and PubMed identifies him as a University of California Los Angeles bioengineering researcher and author. That fits the ecosystem_influencer definition as a professor/scientist providing knowledge and research influence rather than being a primary capital deployer.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No reputable source located shows Aaron S Meyer has documented personal wealth, angel investments, family-office/foundation principal status, or disclosed equity stakes. The available reputable results identify him as an academic scientist rather than a capital owner.","evidence_fund_operator":"No reputable source located shows Aaron S Meyer holding a paid investment management role such as GP, MP, venture partner, managing director, CIO, or fund manager. The available evidence points to an academic appointment, not a fund operation role.","evidence_ecosystem_influencer":"UCLA Profiles lists Aaron S Meyer as an Associate Professor of Bioengineering, and PubMed identifies him as a University of California Los Angeles bioengineering researcher and author. That fits the ecosystem_influencer definition as a professor/scientist providing knowledge and research influence rather than being a primary capital deployer.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T04:55:01.266Z","updated_at":"2026-05-10T12:50:03.625Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/2DCqvykQ","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"79541734-4323-4504-bd5b-e76849a85b3d","public_id":"v8VONpXI","name":"Aaron S. Meyer","canonical_name":"aaron meyer","type":"other","role":"private_investor","bio":"Aaron S. Meyer is a Partner at Wexford Capital LP, where he focuses on the firm's public investments. According to Wexford, he joined the firm in 2014 and became a Partner in 2018. Earlier in his career, he managed long-short portfolios at RBC Proprietary Trading, Millennium Management, and Satellite Asset Management, and also worked at CR Intrinsic Investors, Neuberger Berman, and Goldman Sachs.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/79541734-4323-4504-bd5b-e76849a85b3d.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["public equities","long-short investing","multi-strategy investing","alternative investments","value-oriented investing"],"connections":[{"name":"Charles E. Davidson","relationship":"partner at the same firm, Wexford Capital LP"},{"name":"Joseph M. Jacobs","relationship":"partner at the same firm, Wexford Capital LP"},{"name":"Mark D. Zand","relationship":"partner at the same firm, Wexford Capital LP"},{"name":"Fernando Lopez-Oña","relationship":"partner at the same firm, Wexford Capital LP"},{"name":"John C. Sites, Jr.","relationship":"partner at the same firm, Wexford Capital LP"}],"source_urls":["https://www.wexford.com/leadership","https://www.marketscreener.com/quote/stock/SAILFISH-ROYALTY-CORP-49479360/news/Sailfish-Royalty-2021-Information-Circular-37241114/"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names Aaron S. Meyer as an individual and the cited Wexford leadership page describes him as 'Mr. Meyer' with a personal career history, which is decisive evidence that this is a real human rather than an organization.","classified_at":"2026-05-19T13:15:38.566Z","role_kind":"fund_operator","role_kind_evidence":"[operator] Wexford's official leadership page states that Aaron S. Meyer joined Wexford in 2014, became a Partner in 2018, and focuses on Wexford's public investments. That is a formal paid investment-management role at a fund manager.","is_capital_owner":false,"is_fund_operator":true,"is_ecosystem_influencer":false,"evidence_capital_owner":"No documented personal net worth, angel investing, family-office principal role, or disclosed personal equity stakes were identified in the available reputable sources. The public evidence supports an investment-management role rather than personal capital deployment.","evidence_fund_operator":"Wexford's official leadership page states that Aaron S. Meyer joined Wexford in 2014, became a Partner in 2018, and focuses on Wexford's public investments. That is a formal paid investment-management role at a fund manager.","evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-09T14:13:56.814Z","updated_at":"2026-05-20T05:20:02.268Z","entities":[{"entity_name":"Wexford Capital LP","entity_type":"fund","role":"partner","url":"https://www.wexford.com/leadership"},{"entity_name":"RBC Proprietary Trading","entity_type":"company","role":"portfolio manager","url":null},{"entity_name":"Millennium Management","entity_type":"fund","role":"portfolio manager and analyst","url":null},{"entity_name":"Satellite Asset Management","entity_type":"fund","role":"portfolio manager","url":null},{"entity_name":"CR Intrinsic Investors","entity_type":"fund","role":"investment professional","url":null},{"entity_name":"Neuberger Berman","entity_type":"company","role":"investment professional","url":null},{"entity_name":"Goldman Sachs","entity_type":"company","role":"investment professional","url":null}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/v8VONpXI","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"dece979b-0bab-4a68-b674-0df1e19ccc2b","public_id":"fmNb6UXR","name":"AARP AgeTech Collaborative","canonical_name":"aarp agetech collaborative","type":"accelerator","role":null,"bio":"AARP's startup accelerator for the aging technology ecosystem, providing investment, mentorship, and stakeholder networking to companies developing solutions for aging-related challenges.","url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":false,"person_tags":[],"entity_category":"nonprofit","classification_confidence":{},"classification_reasoning":"The row describes an AARP-branded startup accelerator program rather than a human, and AARP is a nonprofit organization, so this is best treated as an ENTITY.","classified_at":"2026-05-13T14:40:46.144Z","role_kind":null,"role_kind_evidence":"not_relevant: This is an organization, not an individual. Official AARP and AgeTech Collaborative pages describe it as an innovation ecosystem and startup accelerator; there is no documented personal capital attributable to this entity as a person.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":false,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":null,"personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-20T15:05:01.004Z","updated_at":"2026-05-17T04:50:02.670Z","entities":[],"labels":[{"slug":"longevity","confidence":1},{"slug":"startup","confidence":1}],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/fmNb6UXR","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"2e891914-21cd-4136-a47b-f1851409e51d","public_id":"Adw0UOOD","name":"Aarti Jagannath","canonical_name":"aarti jagannath","type":"individual","role":null,"bio":"Aarti Jagannath is a University of Oxford scientist focused on the molecular mechanisms of sleep and circadian rhythm regulation. She is an Associate Professor, Group Leader, and BBSRC David Phillips Fellow in the Sleep and Circadian Neuroscience Institute within Oxford's Nuffield Department of Clinical Neurosciences. She is also an academic founder of Circadian Therapeutics, a spin-out translating circadian research toward clinical applications.","url":null,"linkedin_url":null,"twitter_handle":"@aartijagannath","x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/2e891914-21cd-4136-a47b-f1851409e51d.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["circadian biology","sleep medicine","neuroscience","chronotherapy","molecular biology","translational therapeutics","women in STEM"],"connections":[{"name":"Russell Foster","relationship":"co-founder/academic founder colleague at Circadian Therapeutics"},{"name":"Sridhar Vasudevan","relationship":"co-founder/academic founder colleague at Circadian Therapeutics"}],"source_urls":["https://www.ndcn.ox.ac.uk/team/aarti-jagannath","https://circadiantherapeutics.com/about/"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is for a real human being with a personal name, an academic biography, and university profile links, not a legal or investment entity.","classified_at":"2026-07-03T02:20:05.075Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] The University of Oxford lists Aarti Jagannath as an Associate Professor, Group Leader, and BBSRC David Phillips Fellow researching sleep and circadian biology. Circadian Therapeutics lists her as an Academic Founder, indicating a scientist-founder role that contributes expertise and network rather than fund management.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, family-office role, foundation endowment, or disclosed equity stakes were found in the available public sources. The evidence points to an academic and scientific founder role rather than a capital-deployment role.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"The University of Oxford lists Aarti Jagannath as an Associate Professor, Group Leader, and BBSRC David Phillips Fellow researching sleep and circadian biology. Circadian Therapeutics lists her as an Academic Founder, indicating a scientist-founder role that contributes expertise and network rather than fund management.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":"2026-09-13T14:00:58.148Z","dossier_last_refreshed_at":"2026-09-13T14:02:40.580Z","created_at":"2026-06-24T16:58:07.829Z","updated_at":"2026-09-27T02:20:04.117Z","entities":[{"entity_name":"University of Oxford","entity_type":"advisory","role":"associate professor","url":"https://www.ox.ac.uk/"},{"entity_name":"Nuffield Department of Clinical Neurosciences","entity_type":"advisory","role":"group leader","url":"https://www.ndcn.ox.ac.uk/team/aarti-jagannath"},{"entity_name":"Sleep and Circadian Neuroscience Institute","entity_type":"advisory","role":"BBSRC David Phillips Fellow","url":"https://www.ndcn.ox.ac.uk/team/aarti-jagannath"},{"entity_name":"Circadian Therapeutics","entity_type":"company","role":"academic founder","url":"https://circadiantherapeutics.com/about/"}],"labels":[],"funding_events_count":0,"public_content_count":218,"has_dossier":true,"public_url":"https://eternalsearch.net/investors/Adw0UOOD","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"db97f8f0-b730-43f5-bda4-6ef01877de4d","public_id":"VW17bU99","name":"Abayuba Perna","canonical_name":"abayuba perna","type":"individual","role":null,"bio":"Abayuba Perna is a Uruguayan physician-researcher working in neurology and health-outcomes research. Public sources link him to the Instituto de Neurología at Hospital de Clínicas, Universidad de la República, and to Uruguay’s Fondo Nacional de Recursos through numerous clinical evaluation and outcomes publications. He is also listed by the CDC as an affiliate in the Latin American Epidemiology Network for ALS (LAENALS).","url":null,"linkedin_url":"https://uy.linkedin.com/in/abayuba-perna-aa492634","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/db97f8f0-b730-43f5-bda4-6ef01877de4d.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["neurology","amyotrophic lateral sclerosis","neuroepidemiology","public health","health technology assessment","real-world evidence","rare disease","genetics"],"connections":[{"name":"Carlos N. Ketzoian","relationship":"LAENALS affiliate and co-author from Instituto de Neurología, Hospital de Clínicas"},{"name":"Cristina Vazquez","relationship":"LAENALS affiliate and co-author on ALS research"},{"name":"Gustavo Saona","relationship":"co-author on Fondo Nacional de Recursos and ALS publications"},{"name":"Silvana Albisu","relationship":"co-author on Fondo Nacional de Recursos evaluations"},{"name":"Daniel Pedrosa","relationship":"co-author on Fondo Nacional de Recursos stroke/thrombectomy work"},{"name":"Ronald Salamano","relationship":"co-author on neurology and neuroinfectology research"}],"source_urls":["https://www.cdc.gov/als/php/publications/the-latin-american-epidemiology-network-for-als-laenals.html","https://pmc.ncbi.nlm.nih.gov/articles/PMC12180952/","https://uy.linkedin.com/in/abayuba-perna-aa492634","https://revista.rmu.org.uy/index.php/rmu/article/view/360","https://pubmed.ncbi.nlm.nih.gov/26982990/","https://www.fnr.gub.uy/pagina_de_presentaci/producciones-cientificas/","https://ruc.suc.org.uy/RUC/article/view/185","https://www.elpais.com.uy/vida-actual/primer-panel-genetico-uruguayo-para-distrofias-de-cintura-sienta-bases-para-futuros-diagnosticos"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row names a specific human individual and the cited sources describe Abayuba Perna as a physician-researcher affiliated with academic and public-health institutions, not as an organization.","classified_at":"2026-05-13T00:56:39.792Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] CDC lists Abayuba Perna as a LAENALS affiliate at the Instituto de Neurología, Hospital de Clínicas in Montevideo, Uruguay. Multiple medical publications and profiles identify him as a neurologist/researcher affiliated with Universidad de la República and Fondo Nacional de Recursos, indicating a research and knowledge-network role rather than a capital-deployment role.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal capital deployment, angel investing, family-office principal role, foundation endowment role, or disclosed equity stakes were found in reputable sources. The available evidence describes Perna as a physician-researcher and collaborator on clinical/public-health studies in Uruguay.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"CDC lists Abayuba Perna as a LAENALS affiliate at the Instituto de Neurología, Hospital de Clínicas in Montevideo, Uruguay. Multiple medical publications and profiles identify him as a neurologist/researcher affiliated with Universidad de la República and Fondo Nacional de Recursos, indicating a research and knowledge-network role rather than a capital-deployment role.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T17:50:02.731Z","updated_at":"2026-05-13T00:56:39.792Z","entities":[{"entity_name":"Fondo Nacional de Recursos","entity_type":"institution","role":"researcher / affiliated professional","url":"https://www.fnr.gub.uy/"},{"entity_name":"Universidad de la República","entity_type":"advisory","role":"faculty-affiliated neurologist / researcher","url":"https://udelar.edu.uy/"},{"entity_name":"Hospital de Clínicas, Instituto de Neurología","entity_type":"advisory","role":"neurology affiliate","url":"https://www.hc.edu.uy/"},{"entity_name":"The Latin American Epidemiology Network for ALS (LAENALS)","entity_type":"advisory","role":"affiliate","url":"https://www.cdc.gov/als/php/publications/the-latin-american-epidemiology-network-for-als-laenals.html"}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/VW17bU99","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"bbdc8563-76d4-4455-9f39-e1429663e267","public_id":"SEZGc1u0","name":"Abba Badamasi","canonical_name":null,"type":"individual","role":null,"bio":null,"url":null,"linkedin_url":null,"twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":null,"crunchbase_permalink":null,"sec_cik":null,"interests":null,"connections":[],"source_urls":null,"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row shows a personal name with `type: individual` and no corporate or organizational indicators in any field.","classified_at":"2026-05-15T08:47:02.531Z","role_kind":"ecosystem_influencer","role_kind_evidence":"not_relevant: No documented personal capital deployment, angel investing, equity stakes, or net-worth coverage was found in reputable sources. The available public traces point to professional profiles and a licensed consulting-firm listing, not investment activity.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":null,"evidence_fund_operator":null,"evidence_ecosystem_influencer":"Badamasi Abba appears to be an academic/scientist rather than an investor: SAGE lists him as affiliated with the School of Mathematics and Statistics at Central South University and the Department of Mathematics at Yusuf Maitama Sule University, and PubMed lists the same research affiliations on his journal publications. That fits the ecosystem-influencer category for a scientist/academic, with no evidence he is a primary capital deployer.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-05-06T03:05:01.344Z","updated_at":"2026-05-15T15:20:02.286Z","entities":[],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/SEZGc1u0","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null},{"id":"38f732f8-4306-4f5f-bdad-8805f8730f2f","public_id":"S2G0KwJa","name":"Abbie Morris","canonical_name":"abbie morris","type":"other","role":null,"bio":"Abbie Morris is a UK-based founder, policy and communications advisor, and keynote speaker focused on sustainability, regulation, and impact business growth. She co-founded Compare Ethics, a sustainability compliance platform, and her profile states she raised over £2 million for the company and served enterprise retail clients. Morris now advises leaders and impact businesses on policy, communications, and growth, and has been recognized in Forbes 30 Under 30 Europe.","url":null,"linkedin_url":"https://uk.linkedin.com/in/abbie-morris-1238b538","twitter_handle":null,"x_url":null,"instagram_url":null,"facebook_url":null,"photo_url":"/api/investor-photos/38f732f8-4306-4f5f-bdad-8805f8730f2f.jpg","crunchbase_permalink":null,"sec_cik":null,"interests":["sustainability","climate","ESG","green claims compliance","policy","communications","geopolitics","retail","impact business","entrepreneurship"],"connections":[{"name":"James Omisakin","relationship":"co-founded Compare Ethics together"}],"source_urls":["https://www.abbiemorris.com/","https://uk.linkedin.com/in/abbie-morris-1238b538","https://www.compareethics.com/","https://www.uktechnews.info/2020/10/26/compare-ethics-secures-441k-pre-seed-investment-led-by-ascension-ventures/","https://www.forbes.com/profile/compare-ethics/","https://blueearthsummit.com/news/11-female-founders-to-watch","https://www.f6s.com/company/compare-ethics-ltd"],"is_person":true,"person_tags":[],"entity_category":null,"classification_confidence":{},"classification_reasoning":"The row is for a real individual named Abbie Morris, and the bio describes her personal career as a founder, advisor, and speaker rather than a legal organization.","classified_at":"2026-05-01T22:32:04.466Z","role_kind":"ecosystem_influencer","role_kind_evidence":"[ecosystem] Morris publicly presents herself as a policy, communications, and impact advisor and keynote speaker on her official site, and she is the co-founder/former CEO of Compare Ethics, a venture-backed sustainability compliance company. That fits the ecosystem-influencer category as an operator/advisor providing domain knowledge and network rather than managing investment capital.","is_capital_owner":false,"is_fund_operator":false,"is_ecosystem_influencer":true,"evidence_capital_owner":"No documented personal net worth, angel investing, family office role, foundation endowment, or disclosed personal equity-stake-based wealth was found in reputable public sources. Public coverage describes Morris as an operating founder, advisor, and speaker rather than a capital deployer.","evidence_fund_operator":null,"evidence_ecosystem_influencer":"Morris publicly presents herself as a policy, communications, and impact advisor and keynote speaker on her official site, and she is the co-founder/former CEO of Compare Ethics, a venture-backed sustainability compliance company. That fits the ecosystem-influencer category as an operator/advisor providing domain knowledge and network rather than managing investment capital.","personal_capital_usd":null,"personal_capital_text":null,"personal_capital_source_url":null,"personal_capital_reasoning":null,"personal_capital_checked_at":null,"fund_aum_usd":null,"fund_aum_text":null,"fund_aum_source_url":null,"fund_aum_reasoning":null,"net_worth_estimate":null,"net_worth_source_url":null,"net_worth_reasoning":null,"future_longevity_signal":null,"future_longevity_score":null,"future_longevity_rationale":null,"future_longevity_classified_at":null,"longevity_exposure":null,"longevity_exposure_updated_at":null,"enrichment_level":"basic","public_content_harvested_at":null,"dossier_last_refreshed_at":null,"created_at":"2026-04-20T18:50:22.472Z","updated_at":"2026-05-11T14:03:47.155Z","entities":[{"entity_name":"Compare Ethics","entity_type":"company","role":"co-founder and CEO","url":"https://www.compareethics.com/"},{"entity_name":"AbbieMorris.com","entity_type":"company","role":"founder","url":"https://www.abbiemorris.com/"},{"entity_name":"Confederation of British Industry","entity_type":"company","role":"associate director, London and South East","url":"https://www.cbi.org.uk/"},{"entity_name":"Aequitas Consulting","entity_type":"company","role":"early team member and later senior consultant","url":null}],"labels":[],"funding_events_count":0,"public_content_count":0,"has_dossier":false,"public_url":"https://eternalsearch.net/investors/S2G0KwJa","relevance":"relevant","personal_capital_estimate":null,"fund_aum_estimate":null,"net_worth_estimate_note":null}],"pagination":{"limit":50,"offset":0,"total":6575,"has_more":true},"access_level":"public","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"Eternal Search (eternalsearch.net), powered by Open Longevity","scope":"Applies to data produced by Eternal Search (scores, rationale, extracted structures, summaries, graph). Third-party texts keep their own rights; see text_policy on each record."},"generated_at":"2026-09-27T04:39:42.733Z","family":"investors"}